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6Chapter 1
Introduction
1.1 Background
Eye cancer is an uncommon disease. Despite its low incidence, ocular tumors can be life–
threatening in many cases. Even when the treatment is effective, people living with eye cancer
may suffer from severe side effects that deteriorate their quality of life (Nathan et al., 2015).
The most frequent ocular tumors are uveal melanoma and retinoblastoma. Depending on
the type and extension of the disease several treatment options are available. For small–
to–medium melanomas and retinoblastomas, brachytherapy with radioactive 106Ru/106Rh
plaques offers good outcomes in terms of local control and disease–free survival (Schueler
et al., 2006; Abouzeid et al., 2008; Verschueren et al., 2010; Takiar et al., 2014, 2015; The Amer-
ican Brachytherapy Society – Ophthalmic Oncology Task Force, 2014).
In ophthalmic brachytherapy, like in other radiotherapy modalities, the accuracy of the
radiation dose calculation and delivery may greatly influence patient outcomes. (Nath et al.,
2016). Today, the most used radioisotopes for ophthalmic brachytherapy are 106Ru/106Rh and
125I. The present work is focused on the dosimetry of the 106Ru/106Rh plaques. Although
these plaques have been used for decades, the measurement and calculation of the produced
dose distributions remain challenging tasks (ICRU, 2004). This fact may explain inconsisten-
cies found in the literature on calculation and measurement of dose distributions from these
plaques.
This thesis aims to improve the current knowledge on the features of the absorbed dose
distributions produced by 106Ru/106Rh plaques. First, we will use Monte Carlo simulation of
radiation transport, which is considered the gold standard method in radiation transport cal-
culations, to estimate accurate absorbed dose to water distributions produced by the plaques.
Secondly, we will develop a practical experimental technique to measure in water the pla-
nar dose distributions produced by these plaques. For this experimental validation the EBT3
radiochromic film model will be used which, in turn, requires to characterize this new film
model by Monte Carlo simulation. Both the simulated and measured dose distributions will
be compared with the available literature.
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1.2 Objectives
This thesis aims to improve the knowledge on the dosimetry of 106Ru/106Rh ophthalmic
plaques. To this purpose, the following objectives are defined:
1. To estimate accurate absorbed dose distributions in water for twelve models of 106Ru/
106Rh plaques through Monte Carlo simulations with the PENELOPE code.
2. To study the energy dependence of the EBT3 radiochromic film with different phantom
materials through Monte Carlo simulations with the PENELOPE code.
3. To develop a practical experimental method for measuring the absorbed dose distribu-
tions in water produced by 106Ru/106Rh plaques using the EBT3 radiochromic film to
obtain two–dimensional (2D) dose distributions at several planes of interest.
1.3 Ocular tumors
To better understand ocular tumors and the treatment techniques available a brief description
of the eye anatomy follows (Figure 1.1). The eye is approximately spherical in shape and
it is enclosed by three layers of tissue (Galloway et al., 2006). The outer layer is the sclera,
with a thickness of 0.3 to 1.0 mm, and formed by a white fibrous tissue that covers the eye
except at the front part where is located the cornea, a transparent tissue that allows the light
to enter the eye. The middle layer, the uvea, is formed by three connected structures: the iris,
the ciliary body and the choroid. The iris is located at the anterior part of the uveal tract. It
is the component that gives color to the eye. Its two sets of muscles allow varying the size
of the pupil, the opening in its center that controls the passing of light. The ciliary body is a
ring of muscle surrounding the lens, that may adjust the refractive properties of the lens. The
choroid is composed of a capillary bed that supplies blood to the retina, which is the innermost
layer, and the only one that contains neurons sensitive to the light. Specialized neurons on
the retina named photoreceptors transform the light into electrical signals, which are driven
through a neuron chain to the optic disk, a circular region that connects the retina and the optic
nerve which ultimately sends the visual information to the brain. When the light enters the eye
through the cornea, it traverses the lens and two chambers filled with fluid before arriving to
the retina. The anterior chamber, between the cornea and the lens, is filled with aqueous humor,
which is mostly (98%) water. The volume between the lens and the retina contains the vitreous
humor, a gelatinous substance formed by a network of collagen fibers with large quantities of
water in the interspaces (about 98-99% of the volume is water). The eye globe is covered by
an external layer of tissue named conjunctiva that participates in eye lubrication. The diameter
of the eye at birth is about 16–17 mm and at an age of 13 years old gets its final diameter of
about 24 mm1. As the composition of the structures that account for more than 80% of the
volume of the eye (the aqueous and the vitreous humors) is mostly water, it is reasonable to
1 That diameter corresponds to an emmetropic eye, that is, a normal eye with perfect vision.
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FIGURE 1.1: Anatomy of a normal human eye. Adapted from an image published by
the National Eye Institute, National Institutes of Health, under a Creative Commons
4.0 license (http://creativecommons.org/licenses/by/4.0/).
model the eye as a water sphere for the purpose of Monte Carlo simulations and dosimetric
measurements.
The most frequent malignant intraocular tumors are uveal melanoma and retinoblastoma,
accounting for about 95% of the cases (uveal melanoma 75%, retinoblastoma 20%).
Uveal melanoma is a rare malignancy with a mean incidence of less than one new case
per 100 000 inhabitants and year. It may arise from any component of the uvea, although
the most common is the choroidal melanoma, with more than 90% of the cases. Most of
the choroidal melanomas grow towards the inner part of the eye, producing dome-shaped
tumors. Size of tumors is usually indicated by giving the basal diameter, that is, the approxi-
mate diameter of the tumor base, and the apical height, that is, the distance from the base of
the tumor to the tumor apex, the highest part of the tumor. Choroidal melanomas progress
by developing distant metastases being the liver the most common site. From detection of
metastases the median survival is 2–12 months with a survival probability of 10%–15% after
one year (Nathan et al., 2015). Hence, the treatment of uveal melanoma aims primarily to
avoid metastatic spread and to conserve useful vision in the affected eye, if possible. The op-
timum therapeutic choice depends on the location and size of the melanoma (Damato, 2012).
For large tumors (basal diameter greater than 15 mm and apical height above 10 mm) or when
other therapies fail, the preferred option is proton therapy or enucleation. The latter was the
classic treatment for choroidal melanomas for many years. Plaque brachytherapy with 125I
or 106Ru/106Rh is indicated for small– to medium–sized posterior uveal melanomas, that is,
with basal diameters less than 15 mm and heights below 10 mm. Another therapeutic option
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for medium and large tumors is external beam radiotherapy with photons using stereotactic
techniques. Other techniques not involving ionizing radiation are laser photocoagulation and
transpupillary thermotherapy, reserved to treat small and shallow tumors located away from
critical structures such as the fovea. Surgical alternatives other than enucleation include en-
doresection and sclerouvectomy. Chemotherapy is only indicated as a palliative treatment for
metastatic disease.
Retinoblastoma is the most common intraocular tumor in children, with an incidence of
about one case per 15 000 live births. It is a congenital disease affecting the retina and, in
rare cases, the pineal gland (trilateral retinoblastoma). Approximately 25% of the retinoblas-
tomas are bilateral. A variety of treatment techniques are available depending on the de-
gree of spread of the disease (Olch, 2013). For small localized lesions, focal therapies such
as transpupillary thermotherapy, cryotherapy and laser photocoagulation, alone or in com-
bination with chemotherapy, may be used. For tumors thicker than 4 mm, with limited vit-
reous seeding, or not responding to focal therapies, ophthalmic brachytherapy with 125I or
106Ru/106Rh is an option. When large vitreous seeding is present, or in case of failure of pri-
mary treatments, irradiation of the whole eye globe with external beam radiotherapy, or even
enucleation, may be necessary.
1.4 Ophthalmic brachytherapy
Ophthalmic brachytherapy allows to deliver a high radiation dose to intraocular tumors while
sparing critical structures within the eye. It is less invasive than surgical resection, and pro-
duces less damage to tissues surrounding the tumor than external beam radiotherapy (Dam-
ato, 2012). Today, the most used radioisotopes for ophthalmic brachytherapy are 125I and
106Ru/106Rh. The present work is devoted to improve the dosimetry of 106Ru/106Rh plaques,
which were first introduced by Lommatzsch in 1964 to treat choroidal and ciliary body mela-
nomas. In a retrospective study Lommatzsch et al. (2000) presented the results of long–
term follow–up of patients with small– and medium–sized posterior uveal melanomas, with
follow–up times of at least 22 years, the longest period reported in the literature. They con-
cluded that after 15 years the local control rate was of 63.8% and the cumulative survival rate
of 66.7%. The study by Damato et al. (2005) on small–to–medium choroidal melanomas re-
ported an excellent local control in 93% to 98% of the patients after 5 years. A more recent
study by Verschueren et al. (2010), with 425 patients, found a 5–year actuarial local control of
96% with a 5–year metastases–free survival of 76.5%. About one third of the patients were free
of radiation complications after 5 years, and the enucleation rate at 5 years was only of 4.4%.
The treatment allowed cosmetic preservation in 96% of the cases, but functional preservation
in only one half of the patients.
Although 106Ru/106Rh plaques are popular in Europe, in the United States 125I has been
traditionally the radioisotope of choice, based on the results of the Collaborative Ocular Mela-
noma Study (COMS) (The Collaborative Ocular Melanoma Study Group, 2006; Miras et al.,
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2013). The COMS was a 12–year study that demonstrated the relative equivalence of 125I ther-
apy compared with enucleation to avoid metastatic spread for patients with medium–sized
choroidal melanoma. An unwanted consequence was to establish 125I as the de facto stan-
dard for ophthalmic brachytherapy in North America (The American Brachytherapy Society
– Ophthalmic Oncology Task Force, 2014). However, in 2014 a research group from the MD
Anderson Cancer Center published two papers on the largest cohort of patients treated in the
United States with 106Ru/106Rh plaques for uveal melanoma with excellent outcomes. They
reported actuarial 5-year rates of local control, progression–free survival and overall survival
of 97%, 94% and 92%, respectively (Takiar et al., 2014). In a retrospective study comparing
these results with patients treated with 125I, they found that for 125I these values were 83%,
65%, and 80% (Takiar et al., 2015). The patients treated with 106Ru/106Rh also experienced
less retinopathy and cataracts. They concluded that these results justify the reintroduction of
106Ru/106Rh plaques into the clinical practice in the United States for uveal melanoma, spe-
cially for those with apical heights less than 5 mm.
Two large patient cohort studies exist on 106Ru/106Rh therapy for retinoblastoma. The
study by Schueler et al. (2006) from the Universitätsklinikum Essen included 134 patients
(140 eyes). They reported 5–year local control and eye preservation rates of 94% and 87%,
respectively, with 5–year overall survival rate of 96.4%. The doses given to the tumor apex
were in the range of 88 to 138 Gy. In the high–dose region the rate of late effects was relatively
high, with 54% of cataract incidence, and up to 20% of retinopathy and optic neuropathy.
Abouzeid et al. (2008) studied 39 patients (41 eyes) with lower doses than in the study from
Essen, about 55 Gy. They reported fewer late effects but their outcomes were worse, with
1–year local control and eye preservation rates of 73% and 76%, respectively.
1.5 Characteristics of 106Ru/106Rh plaques
At present, 106Ru/106Rh plaques for ophthalmic brachytherapy are produced by only one
manufacturer (Eckert & Ziegler BEBIG, GmbH. Berlin, Germany), which supplies together
with the plaques a calibration certificate traceable to the NIST (National Institute of Standards
and Technology, Gaithersburg, MD, USA) since 2002. The calibrated absolute absorbed dose
rate to water is stated at a distance of 2 mm from the surface of the plaque, along its central
axis. The certificate also includes depth–dose values measured along the central axis of the
plaque. Measurements are conducted with a plastic scintillator, and the relative uncertainty
in absorbed dose values is stated to be of 20% (k = 2), which includes the 15% uncertainty
(k = 2) of the NIST measurements.
1.5.1 Description and geometry
Figure 1.2 shows the geometrical description of the available 106Ru/106Rh ophthalmic plaques,
with the intended clinical indications. The basic shape of these plaques is a part of a spherical
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FIGURE 1.2: Geometrical description of the available 106Ru/106Rh opthalmic plaques
with the intended clinical indications. The radioactive area is marked hatched. The
plaques studied in this thesis are inside red frames. Courtesy of Eckert & Ziegler
BEBIG, GmbH. Berlin, Germany.
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shell. Depending on the model, the radius of curvature ranges from 12 to 14 mm, and the ex-
ternal diameter of the circle that limits the spherical cap ranges from 10 to 25 mm (ICRU, 2004).
The plaques exhibit rounded edges and eyelets at selected locations such that the plaques can
be sutured to the sclera. The CIA and CIB/CIB–2 models have a cut–out to treat anterior tu-
mors, affecting the ciliary body or the iris, thus preventing irradiation of the cornea. Other
models (COB, COD, COE and COC), not studied in this thesis, have a deeper cut–out to allow
treatment of tumors close to the optic nerve.
A thin layer (∼0.1 µm thick) of the radioisotope is electrolytically deposited on the concave
surface of a 0.2 mm–thick layer of high–purity silver. This layer is encapsulated between the
concave surface of a 0.7 mm–thick layer of silver and the convex surface of a 0.1 mm–thick
layer of silver (exit window) (ICRU, 2004; Astrahan, 2003).
1.5.2 Spectrum of 106Ru/106Rh beta decay
Both 106Ru and 106Rh are pure β− emitting radioisotopes. The beta particles emitted, averaged
over many disintegrations, have a continuous energy spectrum (Figure 1.3). The Fermi theory
of beta decay leads to relatively simple expressions for the shape of the beta spectrum.
106Ru and 106Rh are in secular equilibrium (ICRU, 2004): the 106Ru parent (half–life of
373.6 d) decays via β− to 106Rh (Q–value = 39.4 ± 0.2 keV). The 106Rh daughter (half–life
of 29.8 s) disintegrates via β− to 106Pd (Q–value = 3545.6 ± 5.3 keV). Figure 1.4 shows the
decay schemes of 106Ru and 106Rh. Although there is a gamma component produced by the
transitions to the ground state of 106Pd, and some minor contributions resulting from Auger
emission and electron capture processes (Defrenne and Negret, 2008), the main contributor to
the therapeutic dose is the beta spectrum emitted by 106Rh.
FIGURE 1.3: Beta spectra of 106Ru and 106Rh. Plots taken from the IAEA Live Chart
of Nuclides (https://www-nds.iaea.org/). Reproduced with permission.
C
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13FIGURE 1.4: Decay schemes for 106Ru and 106Rh, pure β− emitters in secular equilibrium. 106Ru decays to the ground state of 106Rh,
that decays with a certain probability to excited states of 106Pd, which in turn deexcite resulting in a complex gamma spectrum. The
Q–values for 106Ru and 106Rh decays are 39.4± 0.2 keV and 3545.6± 5.3 keV, respectively. Plots taken from the IAEA Live Chart of
Nuclides (https://www-nds.iaea.org/), based on data from Defrenne and Negret (2008). Reproduced with permission.
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1.6 Treatment planning with 106Ru/106Rh plaques
In radiotherapy the term treatment planning refers to the process in which a radiation treat-
ment technique is selected and customized for a specific patient. In the case of ophthalmic
brachytherapy with 106Ru/106Rh plaques the treatment planning process involves determin-
ing the location and size of the tumor to be treated, the dose prescription according to the type
and characteristics of the tumor, the choice of an adequate plaque to cover the tumor with the
prescribed dose, the dosimetric study to obtain the dose distribution inside the eye and the
calculation of the treatment time to deliver the prescribed dose. This process is a teamwork
among ophthalmologists, radiation oncologists, medical physicists and other staff.
A computerized treatment planning system is recommended to assist in the planning,
calculation and dose assessment in ophthalmic brachytherapy (Nag et al., 2003). At present,
the state–of–the–art in treatment planning with 106Ru/106Rh plaques is the Plaque Simulator
software (Eye Physics, LLC, Los Alamitos, CA, USA) distributed by the manufacturer of the
plaques. It is a three–dimensional (3D) treatment simulation system initially developed by
Astrahan et al. (1990) for the treatment planning of ocular tumors with 125I seeds. In 2003
Astrahan adapted the software to implement a patch–source model to handle 106Ru/106Rh
plaque calculations (Astrahan, 2003). This method consists of dividing the active layer into
hundreds of patches approximated as small disks uniformly distributed to cover the active
layer of the plaque. The source strength of each patch is adjusted in an iterative process that
uses as input the measured activity of the plaque and the depth–dose distribution stated in
the calibration certificate of the plaques. From version 6.0.1, released in 2014, the software can
use the dose rate measurements at 1 mm from the surface stated in the calibration certificate
by the manufacturer, to take into account the detailed radioisotope distribution of particular
plaques. The software models the eye as composed entirely of water.
To achieve a therapeutic effect, the plaque must be positioned on the sclera covering the
tumor with an adequate safety margin, ideally 2–3 mm. To access the sclera, first the conjunc-
tiva is excised, detaching temporarily ocular muscles if necessary to rotate the eye to visualize
the tumor. Transpupillary illumination may be used to localize and mark the tumor base on
the sclera. When a placement is decided the plaque is positioned and sutured to the sclera
through the plaque eyelets. Then the conjunctiva is repositioned and the eye is rotated again
to the normal position. After the treatment is completed, which takes usually between 1 and
10 days, the plaque is surgically removed.
1.7 Measurement and calculation of absorbed dose distributions pro-
duced by 106Ru/106Rh plaques
Several detectors have been used to measure the dose distributions of 106Ru/106Rh plaques,
including diodes (Soares et al., 2001), diamond detectors (Soares et al., 2001), extrapolation
chambers (Davelaar et al., 1992; Soares et al., 2001), small volume ionization chambers (Soares
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et al., 2001), polymer gel (Chan et al., 2001), thermoluminescent dosimeters (TLD) (Soares
et al., 2001; Kovacˇevic´ et al., 2005; Barbosa et al., 2015), alanine detectors (Soares et al., 2001),
radiochromic films (Taccini et al., 1997; Soares et al., 2001; Kirov et al., 2005; Heilemann et al.,
2015), and plastic (Soares et al., 2001; Kaulich et al., 2005; Flühs et al., 2016) and liquid (Kirov
et al., 2005) scintillators. A good description of the advantages and disadvantages of these
detectors for beta dosimetry is provided in the ICRU Report 72 (ICRU, 2004), which was par-
tially based on a paper by Soares et al. (2001), a key reference on measurement methods for
beta ophthalmic plaques. These authors compared dose data measured with different detec-
tors and by different institutions. They concluded that at that time the measurement uncer-
tainty for 106Ru/106Rh ophthalmic plaques was approximately from 10% to 15%. Clearly, the
accuracy of ophthalmic plaque dosimetry had to be improved.
Because it is difficult to accurately measure dose distributions from 106Ru/106Rh plaques,
it is mandatory to compare the measured data with calculations (ICRU, 2004). The simplest
method for calculating the dose distributions of 106Ru/106Rh ophthalmic plaques is based on
beta–ray point–source kernel integration (Hokkanen et al., 1997). Such calculations are easy
to perform and accurate in a homogeneous medium, but the method fails in the presence of
heterogeneities such as those related to different tissues and the plaque itself (ICRU, 2004). To
partly overcome the limitations of point–source kernel integration, Astrahan (2003) developed
the patch–source model that is currently implemented in the Plaque Simulator software.
The most accurate method for estimating absorbed dose distributions from 106Ru/106Rh
plaques is the Monte Carlo simulation of radiation transport. The Monte Carlo method can
address complex geometrical setups with arbitrary materials, and the obtained results are
often as accurate as, or better than, measured values (ICRU, 2004). A combined point–kernel
and Monte Carlo computer model was used by Davelaar et al. (1992) to estimate the depth–
dose–to–water distributions for CCA and CCB plaque models. The estimated depth–dose was
approximately 15% lower than the manufacturer’s quoted value.
Sánchez-Reyes et al. (1998) were the first authors to apply a well established general–
purpose Monte Carlo code to estimate dose distributions from 106Ru/106Rh plaques. Unfortu-
nately, their study design suffered from some substantial flaws, invalidating their results, as
noted by Brualla et al. (2012).
Cross et al. (2001) presented dose distributions estimated with different Monte Carlo codes
for a non–clinical planar plaque and for a CCB plaque, which are the same plaques examined
by Soares et al. (2001). Poor consistency was observed among the available simulation results.
The authors proposed that differences in the modeling of the plaques, rather than the dif-
ferences inherent to the Monte Carlo codes, might explain the observed discrepancies. They
concluded that further calculations would be necessary to clarify the situation.
Mourtada (2005) performed a comparative dosimetric analysis of 106Ru/106Rh ophthalmic
brachytherapy and external beam proton therapy. The relative dose distributions for both
treatment modalities were estimated in a model eye using the MCNPX Monte Carlo code for
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the CCB plaque, yielding contradictory results: the MCNPX simulation results were consis-
tent with the results obtained by Cross et al. (2001) using MCNP4B and by Taccini et al. (1997)
using GEANT3, whereas the differences found by Cross et al. (2001) between MCNP4B and
ACCEPT 3.0 were similar to those found by Soares et al. (2001) among MCNPX, ACCEPT 3.0,
and film measurement data.
Fuss et al. (2011) simulated the dose distributions produced by a CCX plaque using the
LEPTS Monte Carlo code.
Finally, Brualla et al. (2013) employed the general–purpose Monte Carlo code PENELOPE
to obtain accurate dose distributions for CCA and CCB plaques in a voxelized eye phantom
based on computed tomography scan data. In addition to presenting dose profile data, these
authors estimated the doses to contoured anatomical structures inside the eye.
1.8 Radiochromic films
The selected detector to study in this thesis is the radiochromic film, as it is the only avail-
able detector capable of measuring 2D dose distributions produced by 106Ru/106Rh plaques
in a single measurement. Radiochromic films were introduced in the early 1990s by Inter-
national Specialty Products (Wayne, NJ, USA)2 and supposed a major change respect to the
radiographic films previously used for radiation dosimetry. These new films are relatively
insensitive to visible light and they suffer a color change by polymerization reactions in re-
sponse to irradiation avoiding the need of a chemical development process. Radiochromic
films are nowadays routinely used for radiation dosimetry in external beam radiotherapy and
brachytherapy applications (Devic, 2011) such as verification of treatment plans, quality as-
surance of clinical linear accelerators and radioactive sources, and in–vivo dosimetry. Several
types of radiochromic films were developed, with important differences in the composition
of the active layers (Blackwell et al., 1998), including models aimed for radiotherapy applica-
tions, namely, the EBT3, EBT2 and EBT3. The EBT and EBT2 models are now outdated since
the EBT3 model was introduced in 2012.
In principle, the characteristics of radiochromic films make them an almost–ideal detector
for beta dosimetry: high spatial resolution, self–developing, near tissue equivalent, a very thin
detection layer and relatively low energy dependence (Devic, 2011). However, few publica-
tions report data from measurements of 106Ru/106Rh plaques with radiochromic films (Taccini
et al., 1997; Soares et al., 2001; Kirov et al., 2005; Heilemann et al., 2015). The first publications
found as a major limitation the large variations in the thickness of the active4 layer present in
the early film models (Taccini et al., 1997; Soares et al., 2001). Soares et al. (2001) reported a
measurement relative standard uncertainty of 7.5% for measurements at a plane perpendic-
ular to the symmetry axis of the plaques, and using a phantom made of WT1 plastic water
material.
2 Now incorporated to Ashland Specialty Ingredients, Wayne, NJ, USA.
3 EBT stands for External Beam Therapy.
4 That is, the layer with the emulsion sensitive to radiation.
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The ‘second generation’ of radiochromic films (MD–55–2 and HD–810 models) were used
by Kirov et al. (2005) to measure dose distributions of a CCX plaque in a plastic phantom,
stating a relative standard uncertainty of 15%.
The initial problems with thickness variations were partially solved with the EBT2 model,
by adding a yellow dye to the active layer which allowed to compensate for non–uniformities
in the active layer thickness. The most recent EBT3 model also introduced changes to the ac-
tive layer composition to improve the energy dependence in a wide energy range. As this is
the film model used in this thesis, we considered relevant to confirm the supposed improve-
ment in energy dependence, and to study the influence of different phantom materials in the
energy dependence of the EBT3 model. These topics will be addressed in chapter 3.
1.9 The Monte Carlo method for radiation transport
The term radiation transport refers to the physical phenomenon consisting in the propagation
of radiation (directly or indirectly ionizing) through matter. In this process, radiation with a
certain energy propagates in a material medium, interacting with it and transferring energy
to the medium and to secondary particles. The quantity that represents the probability of
occurrence of a given interaction between radiation and matter is named the cross section for
the interaction of interest. Although the physical principles that govern the individual in-
teractions between radiation and matter are well known, when a high number of particles or
non–trivial geometries are considered, the mathematical complexity of the problem is too high
to be solved by analytical methods without introducing approximations or simplifications.
The Monte Carlo method is a stochastic technique based on the use of (pseudo–)random
numbers, capable of simulating mathematical or physical experiments (Kalos and Whitlock,
2008). A basic application of the Monte Carlo method is numerical integration. The method
has been successfully applied to a wide range of disciplines, including physics, engineering,
finance, etc. In particular, the method is well suited to the simulation of the interactions of
radiation with matter.
The Monte Carlo simulation of radiation transport is a simple process (see e.g. Rodríguez
Castillo (2015)): (i) A primary particle is generated by specifying its initial state variables (type
of particle, position, flight direction, and kinetic energy). (ii) The particle is moved to a new
position along a straight line following the flight direction. The length of flight is obtained
by sampling the corresponding path length probability density function characteristic of the
particle and the medium. (iii) The particle suffers an interaction, which is randomly selected
according to the probabilities given by the cross sections of the possible interactions consid-
ered in the simulation. (iv) The interaction is simulated, which results in a change in the state
variables of the primary particle and possibly in the generation of secondary particles. At this
step, the relevant quantities for the simulation are tallied (e.g. the energy deposited in a detec-
tor). (v) The process from step (ii) is repeated, until the initial particle is absorbed or escapes
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from the geometry simulated (a particle is considered locally absorbed when its kinetic en-
ergy falls below a specified energy threshold). Secondary particles are simulated in the same
way. The simulation of a primary particle and all their descendants is named a history or a
shower. By simulating a large number of histories, average values of macroscopic observables
of interest such as the energy deposition, can be estimated. Owing to the random nature of
the Monte Carlo simulation the tallied observables have an inherent statistical uncertainty.
Although the simulation algorithm is conceptually simple, if the number of interactions
per unit path length is high, as it is the case for electrons, the simulation could become ex-
tremely slow. Different simulation schemes are used to handle this situation. In a detailed
simulation all the interactions suffered by a particle are simulated one by one. This scheme is
adequate to simulate photons, as the number of interactions per unit length is low. Electrons,
however, may suffer thousands of interactions, and most of them are elastic, that is, the ki-
netic energy of the electron is conserved and its direction of movement changes only slightly.
In others, the energy loss is only of a few tens of electron–volts. In most cases, it results very
inefficient to simulate all these soft events one by one5. Most of the Monte Carlo codes for the
simulation of radiation transport rely on the so–called condensed transport schemes, which use
multiple–scattering theories that simulate in an approximate way the global effect of a large
number of events occurring in a track segment of a given length. Each track is approximately
simulated as a series of steps of a specified length much larger than the mean free path length
of the real collisions (Fernández-Varea et al., 1993). Depending on how the value of this step
length is determined, the condensed transport algorithms are classified in two classes, follow-
ing the terminology coined by Berger (1963):
• Class I algorithms: a fixed step length is used. This approach fails close to the interface
between different materials, as the step length may not be contained in a single medium,
which is a necessary condition to apply multiple–scattering theories.
• Class II algorithms: the step length is randomly selected. The interactions are classified
as soft events if the energy loss and the changes in direction are below predefined cutoffs.
The rest of the interactions are classified as hard events and are simulated in a detailed
way. The choice of the energy and angular cutoff values is usually responsibility of the
user, and not a characteristic of the physical processes involved.
The purpose of a simulation is the estimation of the expected values of some quantities of
interest. Any quantity of interest Q (e.g., the energy deposited in a detector), is estimated as
the arithmetic mean of the tallied values from a large number N of independently simulated
histories:
Q =
1
N
N
∑
i=1
qi, (1.1)
where qi is the tallied contribution of the i–th history to the quantity Q, that is, the contribution
of all the particles pertaining to the i–th history. If the number of simulated histories N is
5 Some exceptions are simulations of low energy electrons, or geometries involving thin foils.
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sufficiently large, this mean converges to the expected value 〈Q〉. The standard statistical
uncertainty inherent to the Monte Carlo estimate for the quantity Q is given by:
σQ =
√√√√ 1
N
[
1
N
N
∑
i=1
q2i −Q
2
]
. (1.2)
At present, there is a variety of general–purpose Monte Carlo codes (software packages)
for the simulation of radiation transport, such as EGSnrc (Kawrakow et al., 2009), Geant 4
(Agostinelli et al., 2003), MCNP (Forster et al., 2004) and PENELOPE (Baró et al., 1995; Sempau
et al., 1997; Salvat et al., 2009; Salvat, 2015a), which have been successfully applied to a wide
range of fields, including medical physics.
The simulations computed for this thesis were performed with PENELOPE6 (Baró et al.,
1995; Sempau et al., 1997; Salvat et al., 2009; Salvat, 2015a), a Monte Carlo code written in For-
tran that simulates the coupled transport of electrons, positrons and photons with energies
ranging from 50 eV to 1 GeV in materials consisting of homogeneous bodies with arbitrary
chemical compositions. For photons, PENELOPE performs detailed simulation. Electrons and
positrons are simulated using a mixed class II scheme. Collision events are classified as hard
or soft according to the energy loss and the change in the particle direction relative to certain
user–defined threshold values. The algorithm is controlled by eight parameters: EABS (for
photons, electrons and positrons), C1, C2, WCC, WCR and DMAX. EABS are the absorption
energies defined for photons, electrons and positrons. If the energy of a particle becomes
smaller than the corresponding absorption energy the particle is assumed to be locally ab-
sorbed. The rest of the parameters only apply to the simulation of electrons and positrons. C1
is the average angular deflection due to a hard elastic collision and all previous soft collisions.
C2 controls the maximum allowed value for the average fractional energy loss in a step. WCC
and WCR are energy cutoffs for hard inelastic collisions and hard Bremsstrahlung emission,
respectively. If the user sets C1 = C2 = WCC = 0 and WCR with an arbitrary negative value,
PENELOPE performs a detailed simulation for electrons and positrons (Salvat, 2015a). Finally,
DSMAX is an upper limit for the step length. The values given to these parameters deter-
mine the accuracy and speed of the simulation. The user must set the values of the simulation
parameters for each material of the geometry considered in the simulation. PENELOPE mod-
els the system geometry with bodies limited by constructive quadric surfaces. The geometry
subroutines are enclosed in the geometry package PENGEOM (Almansa et al., 2016).
Since the first version of PENELOPE was released in 1996, many improvements have been
added to the physics interaction models, to the tracking algorithm, and to the PENGEOM sub-
routines (Salvat, 2015b). PENELOPE has found many applications in the medical physics field,
including radiation dosimetry (Sempau and Andreo, 2006; Erazo et al., 2014), radiotherapy
(Seco and Verhaegen, 2013; Rodríguez et al., 2013), x–ray imaging (Badano and Sempau, 2006),
and nuclear medicine (España et al., 2009). Comprehensive experimental benchmarks of the
6 The acronym PENELOPE initially standed for PENetration and Energy LOss of Positrons and Electrons. Pho-
tons were introduced later.
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reliability of the PENELOPE interaction models and tracking algorithms are available (Sem-
pau et al., 2003; Faddegon et al., 2008, 2009), both for photons and electrons/positrons. The
most recent version of the PENELOPE software package and the associated manual are freely
available from the OECD Nuclear Energy Agency Data Bank (http://www.nea.fr) and from the
Radiation Safety Information Computational Center (http://www-rsicc.ornl.gov).
1.10 Thesis outline
The thesis is structured in six chapters, being this introduction the chapter 1. The follow-
ing chapters present the methods and results developed in the thesis to fulfill the objectives
outlined at the beginning of this chapter.
Chapter 2 presents the results of Monte Carlo simulations for twelve 106Ru/106Rh plaque
models using the PENELOPE code, which include the plaque models most commonly used in
the clinical practice. These results are compared with the available published data, solving in-
consistencies found among the published data. The obtained absorbed dose distributions rep-
resent the most comprehensive dataset available in the literature on Monte Carlo simulation of
106Ru/106Rh plaques for ophthalmic brachytherapy. For some of these plaques, the simulation
results from this research are the first dose data reported. Most of the content of this chapter
was published by the author of this thesis in the Medical Physics journal (Hermida-López, 2013,
2016). The chapter includes also unpublished data on the influence of the gamma component
produced by the transitions to the ground state of 106Pd on the simulation of 106Ru/106Rh
plaques, which is neglected in all available published works. The numeric dose data pre-
sented may be useful for quality assurance of treatment planing systems, and may constitute
the basis of a consensus dataset for 106Ru/106Rh plaques, such as the already existing for other
brachytherapy sources.
Chapter 3 analyzes the energy dependence of the EBT3 radiochromic film through Monte
Carlo simulations. It represents the first study on the influence of the phantom material on
the energy dependence of the EBT3 film. Several solid phantom materials commonly used
for film dosimetry are studied and compared to water, which is the reference medium for
radiation dosimetry. The results from this chapter are needed to assess a component of the
experimental uncertainty of the measurements presented in chapter 4. However, these results
have a wider scope, as the EBT3 model is the current de facto standard for film dosimetry in
radiotherapy and other fields. The contents of this chapter were published by the author of
this thesis and coauthors in the Medical Physics journal (Hermida-López et al., 2014).
Chapter 4 presents the experimental validation of the simulation results through measure-
ments of absorbed dose distributions of 106Ru/106Rh plaques with the EBT3 radiochromic
film. Few publications report measurement data of 106Ru/106Rh plaques with radiochromic
film, and all of them use plastic phantoms. In this chapter, two novel experimental setups
are developed to measure absorbed dose distributions of 106Ru/106Rh plaques with the EBT3
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film in water. These practical setups may ease the quality assurance procedures to the users
of 106Ru/106Rh plaques.
In chapter 5 a discussion is presented, where the scope and limitations of the results from
the thesis are analyzed. Moreover, it is discussed how the obtained results may influence
the clinical practice of 106Ru/106Rh ophthalmic brachytherapy and future research lines are
suggested.
Finally, chapter 6 briefly summarizes the thesis conclusions, and the major findings re-
garding the objectives outlined in chapter 1.
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Chapter 2
Monte Carlo simulation of 106Ru/106Rh
ophthalmic plaques
2.1 Introduction
Beta–ray emitting 106Ru/106Rh ophthalmic plaques are routinely used to treat ocular tumors,
mainly choroidal melanomas and retinoblastoma, with good clinical outcomes (Schueler et al.,
2006; Abouzeid et al., 2008; Verschueren et al., 2010; Takiar et al., 2014, 2015; The American
Brachytherapy Society – Ophthalmic Oncology Task Force, 2014). Factors that are relevant to
the clinical outcome include the tumor dose coverage and the dose to normal tissue inside
the eye. Because the beta radiation used for therapeutic applications produces steep dose
gradients, an accurate knowledge of the generated absorbed dose distributions is essential for
treatment planning and clinical dose assessment (ICRU, 2004). Although 106Ru/106Rh plaques
were introduced in 1964, the measurement and calculation of absorbed dose distributions re-
main challenging tasks today. Difficulties arise because of the small range of the emitted
beta particles (only a few millimeters in water), the small volume irradiated, and the afore-
mentioned steep dose gradients. The shape of the plaques (spherical shells) also produces
experimental difficulties. The most accurate method to compute dose distributions produced
by 106Ru/106Rh plaques is Monte Carlo simulation of radiation transport (ICRU, 2004).
Despite that there are 16 models of 106Ru/106Rh plaques commercially available, the major-
ity of the published studies on Monte Carlo simulation of 106Ru/106Rh plaques have focused
on the most commonly used models (CCA and CCB), and for some models, namely the CXS
and the CCD, there are no published data. The work presented in this chapter aimed to ac-
curately estimate the absorbed dose–to–water distributions of 12 clinical 106Ru/106Rh plaque
models (CCA, CCB, CCC, CCD, CCX / CCY / CCZ, CXS, CGD, CIA and CIB/CIB2) using
the Monte Carlo code PENELOPE. The results were compared with published data when avail-
able. The work presented in this chapter represents the most comprehensive study to date on
Monte Carlo simulation of 106Ru/106Rh plaques. Most of the content was published in the
Medical Physics journal by the author of this thesis (Hermida-López, 2013, 2016). Addition-
ally, unpublished data on the influence of the 106Pd gamma spectrum on the simulations of
106Ru/106Rh plaques are also presented in this chapter.
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FIGURE 2.1: Cross section of a clinical 106Ru/106Rh plaque (not to scale for clarity),
showing the diameter D, the active diameter Da, the height h, and the radius of
curvature r. The total thickness of the plaques is 1 mm.
2.2 Methods
2.2.1 Geometric modeling of the 106Ru/106Rh plaques
The geometric modeling of the plaques was based on data from the ICRU Report 72 (ICRU,
2004) and from the manufacturer’s manual for the plaques7. Figure 2.1 shows a cross section
of a typical 106Ru/106Rh plaque. Table 2.1 shows the geometrical dimensions of the plaques
studied in this chapter. The thickness of the radioisotope layer on the plaques is∼0.1 µm (As-
trahan, 2003) [in some publications, it is incorrectly stated that the thickness is 0.2 mm (Taccini
et al., 1997)]. The radioisotope layer thickness in the simulations was considered negligible
and the radioisotope was assumed to be homogeneously distributed over the active area. This
is an approximation, as surface dose rate inhomogeneities of up to 20% respect to the value at
the central axis have been described (Eichmann et al., 2009). The plaques were simulated as
being immersed in a 6 cm–radius water sphere, concentric with the plaque.
In addition to the clinical 106Ru/106Rh plaques, a planar non–clinical plaque (CCB 570
model) (Soares et al., 2001; Cross et al., 2001) was also simulated. This plaque consists of a
disk with an active diameter of 20.5 mm. The active layer is mounted on a silver backing
with a 0.9 mm thickness and is covered by a silver exit window with a 0.1 mm thickness. A
total diameter of 21 mm was assumed. The planar design of this plaque allows measuring the
produced dose distribution easily, as a detector can be positioned very close to the surface of
the plaque, as opposed to the concave clinical plaques. The obtained results from the simula-
tions in this work were compared with published data (Soares et al., 2001; Cross et al., 2001).
As variations in thickness of the exit window of up to 6 µm have been reported (Eichmann
et al., 2009), additional simulations were run modifying the thickness of the exit window of
the planar plaque in ± 10 µm to study how these variations may affect the results.
7Eckert & Ziegler BEBIG GmbH, User’s manual Ru–106 eye plaques (Rev. 10), (2011).
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TABLE 2.1: Geometrical dimensions of the clinical 106Ru/106Rh plaques simulated
in this chapter, as taken from the ICRU 72 Report (ICRU, 2004). The plaques CCX,
CCY and CCZ only differ in the number and position of the eyelets. It happens the
same for the CIB and CIB–2 models.
Model DiameterD (mm)
Height
h (mm)
Active diameter
Da (mm)
Radius of curvature
r (mm)
CCA 15.3 3.3 13.0 12.0
CCB 20.2 5.4 17.8 12.0
CCC 24.8 8.0 22.5 13.0
CCD 17.9 4.3 15.5 12.0
CCX–Y–Z 11.6 2.3 9.5 12.0
CXS 11.6 2.3 7.7 12.0
CGD 22.3 6.1 19.9 13.0
CIA 15.3 3.3 13.0 12.0
CIB/CIB–2 20.2 5.4 17.8 12.0
2.2.2 Simulation conditions
Simulations in this chapter were performed using version 2008.1 of PENELOPE (Baró et al.,
1995; Salvat et al., 2009)8, except the simulations from subsection 2.3.11, which were run with
version 2014. The 106Rh beta spectrum used in the simulations was taken from the ICRU Re-
port 72 (ICRU, 2004) (Figure 2.2). The 106Ru beta spectrum (Emax = 39 keV) and the gamma
spectrum from the 106Pd excited states (see Figure 1.4) were not considered, as previous works
have done, to compare with the results in the literature. The range of 39 keV electrons in sil-
ver is less than 0.01 mm; therefore, these particles cannot traverse the exit window of these
plaques, with a thickness of 0.1 mm. Meanwhile, gamma radiation has a minor effect on the
dose distributions obtained at depths of clinical interest (0–8 mm); it is assumed in the liter-
ature that its effect is only appreciable at greater depths. The validity of this approximation
was assessed, as no previous publication reported detailed values on the influence of the 106Pd
gamma photons on the depth–dose distribution of these plaques. The beta spectra from the
ICRU Report 72 were calculated using empirical expressions which included all the compo-
nents with contributions greater than 0.3%. The uncertainties of beta spectra calculated with
this method are estimated to be of a few percent. More details on the calculation models can
be found in the ICRU Report 56 (ICRU, 1997).
The materials (water for the phantom and silver for the plaque) were chosen from the
PENELOPE material library. The mass density was 1.00 g cm−3 for water and 10.50 g cm−3 for
silver. The following values for the PENELOPE simulation parameters were chosen for both
water and silver: EABS(e−) = EABS(e+) = 70 keV, EABS(γ)= 10 keV, C1 = C2 = 0.1, WCC
= 30 keV, and WCR = 4 keV. It was verified for some test cases that the dose distributions
obtained with these parameters were compatible with those obtained using a detailed simu-
lation, within statistical uncertainties below 0.6% (k = 3).
8 Version 2008.1 corrects some minor bugs respect to version 2008.
Chapter 2. Monte Carlo simulation of 106Ru/106Rh ophthalmic plaques 25
 
be
ta
	ra
ys
/(
de
ca
y	M
eV
)
0.0
0.1
0.2
0.3
0.4
0.5
Energy	(MeV)
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
FIGURE 2.2: 106Rh beta spectrum used as source for the simulations of this chapter,
taken from the ICRU Report 72 (ICRU, 2004).
Cylindrical symmetry was not considered in the simulations. Although this choice may
not appear to be optimal for the symmetric plaque models due to an unnecessary increase in
computation time, this approach was preferred to take advantage of the predefined PENELOPE
routines, thus reducing the programming effort and the amount of time that was necessary to
set up the simulations.
For each run, 2× 108 histories were simulated, which resulted in a statistical uncertainty
of approximately 1–2% (k = 3) for most of the estimated dose values. The absorbed dose
was scored in a grid composed of 63 × 63 × 63 bins of 0.5 × 0.5 × 0.5 mm3 in a Cartesian
coordinate system whose origin was at the intersection of the central axis of the plaque with
its inner surface. The grid ranged from −15.75 mm to +15.75 mm in each direction.
For each plaque the following data are presented:
• Depth absorbed dose distributions in 0.5 mm steps from the inner surface of the plaque
to a depth of 10.0 mm. Doses at 0 depth of the depth–dose curves were extrapolated
from a fit using the doses in the depth range of 0.5–6.0 mm.
• Lateral absorbed dose distributions at six depths of clinical interest (1, 2, 3, 4, 6 and
8 mm, in 0.5 mm steps) and outward from the central axis of the plaques. The maximum
lateral distances of the lateral dose profiles were chosen in such a manner that the whole
profiles are inside the water phantom for the different depths.
The bins crossing the interface between the plaque and the water phantom are subject to
a partial–volume effect, as part of their volume contains silver and other part contains water.
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As the mass density and the atomic number are much higher for silver than that for water,
the energy deposited in those bins, although it is correctly tallied, is not representative of the
actual energy deposited at the surface of the plaque. Hence, the relative depth dose values
for zero depth were extrapolated from a fit using doses in the depth range of 0.5–6.0 mm. The
length of the lateral dose profiles was adjusted for each depth to include bins containing water
only, avoiding bins crossing the surface of the plaque.
Monte Carlo simulations provide inherently absolute dose results (in eV/g per history). If
we know the activity of the plaque (in MBq), we could obtain the dose rate per unit of activity
(mGy h−1 MBq−1) for a specific plaque. However, we chose to give the Monte Carlo results
of this chapter in relative values for the following reasons: (i) to ease the comparisons with
published results (measurements and simulations), the vast majority of which are given as
relative dose distributions; and (ii) to give dose distributions typical of a plaque model, rather
than those of a specific plaque.
Relative doses are presented in tabulated form to simplify future comparisons and to avoid
the additional uncertainties involved in reading values directly from graphs (ICRU, 2004). The
uncertainty bars of the graphs represent the statistical uncertainty of the doses estimated, with
a coverage factor9 of k = 3. Unless otherwise indicated, the doses and statistical uncertainties
in this chapter are normalized to the doses at a depth of 1 mm along the central axis. The
results were compared with published data as well as with the data provided in the calibration
certificates of the available plaques, and with reference data from the manufacturer.
2.3 Results and discussion
A summary of the relative depth–dose data is presented in Table 2.2. The lateral relative dose
profiles at several depths of clinical interest are shown in Tables 2.3 and 2.4 for symmetric and
asymmetric plaques, respectively.
9 The coverage factor is the numerical factor that multiplies the combined standard uncertainty to obtain an
expanded uncertainty.
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TABLE 2.2: Relative absorbed dose data in depth estimated with PENELOPE for
the plaques simulated in this work. Absorbed dose and uncertainty values (k = 3)
are normalized to a percentage of 100% at 1 mm depth. Doses at 0 depth were
extrapolated from a fit using values in the depth range of 0.5–6.0 mm.
Plaque Planar CCB 570 CCA CCB CCC CCD CCX–Y–Z CXS CGD CIA CIB/CIB2
Depth (mm)
0.0 134.9 126.8 124.8 123.8 124.6 131.7 136.9 123.6 141.7 141.8
0.5 117.5 113.4 112.4 111.9 112.3 115.8 118.5 111.8 120.8 120.9
1.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
1.5 84.8 87.7 88.3 88.3 87.7 84.8 82.8 88.9 83.0 84.5
2.0 71.4 75.5 77.9 77.6 77.1 71.4 67.0 77.9 69.4 71.6
2.5 59.4 64.5 68.2 68.7 66.9 58.5 53.7 68.3 58.1 61.6
3.0 50.0 55.0 59.3 59.0 57.5 48.0 42.3 58.8 48.6 52.4
3.5 41.5 45.9 51.6 51.5 48.9 38.6 33.1 51.3 40.1 44.5
4.0 34.1 38.2 43.9 44.7 41.7 30.8 25.7 44.0 33.0 37.7
4.5 27.9 31.5 37.5 38.2 34.9 24.4 20.0 36.9 27.2 32.2
5.0 22.6 25.8 31.5 32.4 28.8 19.1 15.3 31.4 21.9 26.9
5.5 17.8 20.5 26.4 27.3 23.8 15.0 11.8 26.7 17.7 22.5
6.0 14.3 16.5 21.7 23.0 19.5 11.6 9.0 22.2 14.3 18.3
6.5 11.2 13.0 17.9 19.4 15.7 8.9 6.8 18.3 11.1 15.0
7.0 8.8 10.3 14.5 15.9 12.6 6.8 5.0 15.1 8.8 12.1
7.5 6.7 8.0 11.8 13.3 9.9 5.2 3.8 12.0 6.8 9.7
8.0 5.0 6.1 9.2 10.7 7.8 3.9 2.9 9.5 5.2 7.6
8.5 3.8 4.8 7.2 8.7 5.9 2.9 2.2 7.6 4.0 6.1
9.0 2.9 3.6 5.6 6.8 4.5 2.2 1.6 6.0 3.0 4.7
9.5 2.1 2.6 4.3 5.4 3.4 1.5 1.1 4.7 2.2 3.5
10.0 1.5 1.9 3.2 4.2 2.5 1.1 0.8 3.5 1.6 2.7
Relative average
uncertainty (%) (k = 3) 0.5 0.3 0.5 0.6 0.4 0.2 0.2 0.6 0.3 0.4
Chapter 2. Monte Carlo simulation of 106Ru/106Rh ophthalmic plaques 28
TABLE 2.3: Lateral relative absorbed dose profiles at several depths of clinical interest for the
symmetric plaques CCB–570 (planar), CCA, CCB, CCC, CCD, CCX/Y/Z, CXS, and CGD.
Data are normalized at 1 mm depth at the central axis. The maximum statistical uncertainty
(k = 3) is less than 2% for all depths and plaques. The lateral distance values are repeated
for each plaque to improve legibility.
Plaque Depth (mm) Lateral distance from the central axis (mm)
Planar
CCB 570 0.0 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5 10.5 11.5
1.0 100.0 100.0 99.3 99.3 99.3 97.5 96.5 93.2 86.2 70.8 38.2 14.7
2.0 71.4 71.0 70.7 70.4 69.8 69.2 66.4 63.1 56.7 44.2 28.9 15.8
4.0 34.1 33.7 33.7 33.4 32.5 31.9 29.7 27.3 23.4 18.9 14.1 9.4
6.0 14.3 14.2 14.0 13.9 13.4 13.2 12.1 10.8 9.6 7.7 5.9 4.2
8.0 5.0 5.0 4.9 4.9 4.9 4.5 4.2 3.7 3.2 2.7 2.0 1.5
CCA 0.0 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5 10.5 11.5
1.0 100.0 102.1 105.1 109.6 122.6
2.0 75.5 76.9 78.7 81.3 84.1 83.7
3.0 55.0 55.4 55.8 55.8 54.3 46.6 27.2
4.0 38.2 38.5 38.3 36.9 34.0 27.6 18.2 9.2 4.0 1.7 0.8 0.3
6.0 16.5 16.4 51.7 14.6 12.9 10.6 7.7 5.0 2.9 1.6 0.8 0.4
8.0 6.1 6.0 5.7 5.3 4.5 3.8 2.8 2.1 1.3 0.8 0.5 0.2
CCB 0.0 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5 10.5 11.5
1.0 100.0 102.4 106.0 111.9
2.0 77.9 79.9 83.4 88.4 95.2 105.6
3.0 59.3 60.5 63.4 68.2 73.6 80.9 90.8
4.0 43.9 44.8 47.0 50.6 54.3 58.9 64.8 70.1
6.0 21.7 22.3 23.6 24.5 25.7 26.8 26.5 23.3 16.9 9.4 3.3 0.9
8.0 9.2 9.6 9.6 10.3 10.4 10.4 9.7 8.5 6.4 4.3 2.5 1.3
CCC 0.0 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5 10.5 11.5
1.0 100.0 102.3 105.4 111.2 120.1
2.0 77.6 79.7 83.9 88.3 96.1 105.5 118.2
3.0 59.0 61.8 64.6 69.7 75.6 85.1 94.8 108.7
4.0 44.7 46.4 48.2 52.8 58.9 66.3 76.0 78.7 102.5
6.0 22.9 24.5 26.0 29.0 32.3 37.9 43.9 51.9 61.2 71.9 87.5
8.0 10.7 11.3 12.1 13.8 16.0 18.8 21.6 23.9 26.7 26.4 20.9 11.6
CCD 0.0 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5 10.5 11.5
1.0 100.0 101.6 105.1 110.3 123.4
2.0 77.1 78.5 81.4 85.8 92.1 99.7
3.0 57.5 58.4 60.1 63.7 67.4 70.7 73.3
4.0 41.7 42.2 43.6 45.0 46.4 46.3 41.7 28.3 11.5
6.0 19.5 19.4 19.6 19.8 19.1 17.6 14.8 11.0 6.7 3.6
8.0 7.7 7.7 7.7 7.6 7.2 6.4 5.2 4.1 2.9 1.8 1.1
CCX/Y/Z 0.0 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5 10.5 11.5
1.0 100.0 100.7 101.5 101.7
2.0 71.4 70.3 68.0 60.4 40.2 15.2
3.0 48.0 46.5 42.8 35.9 24.9 13.4 6.2
4.0 30.8 29.6 26.6 22.0 15.9 9.9 5.4 2.8 1.4 0.7 0.3 0.1
6.0 11.6 10.9 9.9 8.3 6.4 4.5 2.9 1.7 1.0 0.5 0.3 0.1
8.0 3.9 3.8 3.3 2.8 2.2 1.7 1.2 0.8 0.4 0.3 0.1 0.1
CXS 0.0 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5 10.5 11.5
1.0 100.0 99.2 95.2 71.8
2.0 67.0 64.0 55.8 38.7 18.2 7.4
3.0 42.3 39.2 33.1 23.9 14.1 7.2 3.4
4.0 25.7 23.6 20.0 15.0 9.8 5.7 3.1 1.6 0.8 0.4 0.2 0.1
6.0 9.0 8.3 7.1 5.6 4.1 2.8 1.7 1.0 0.5 0.3 0.1 0.1
8.0 2.9 2.7 2.4 2.0 1.5 1.1 0.7 0.5 0.3 0.1 0.1 0.0
CGD 0.0 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5 10.5 11.5
1.0 100.0 101.8 105.8 111.1 120.3
2.0 77.8 79.5 83.2 87.8 95.0 103.9 115.4
3.0 58.7 60.8 63.8 67.9 73.8 81.8 92.3 103.8
4.0 44.1 44.8 47.2 50.8 55.8 62.6 70.1 79.0 91.7
6.0 22.2 22.7 23.8 25.8 28.5 30.9 33.6 35.0 32.9 21.0 11.3
8.0 9.5 10.0 10.5 11.4 12.1 12.9 13.6 13.1 11.5 8.8 5.6 2.9
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TABLE 2.4: Lateral relative absorbed dose profiles at several depths of clinical interest for the asym-
metric plaques CIA and CIB/CIB–2. Data are normalized at 1 mm depth along the central axis. The
maximum statistical uncertainty (k = 3) is less than 2% at all depths and for all plaques. Axes conven-
tion is sketched on Figure 2.12.
Plaque Depth (mm) Lateral distance from the central axis (mm)
CIA
X axis −9.5 −8.5 −7.5 −6.5 −5.5 −4.5 −3.5 −2.5 −1.5 0.0 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5
1.0 151.8 134.2 126.5 118.8 100.0 45.0 19.8 9.6 5.0 2.7 1.5 0.8 0.4 0.2
2.0 104.0 103.1 98.5 92.8 86.3 69.4 40.2 23.1 12.5 6.8 3.7 2.0 1.0 0.5 0.3
3.0 12.1 33.9 57.5 66.1 67.3 64.7 60.1 48.6 31.4 20.5 12.4 7.2 4.0 2.2 1.2 0.6 0.3
4.0 4.8 11.3 22.2 33.8 41.0 43.6 43.1 40.4 33.0 22.9 16.2 10.5 6.4 3.8 2.1 1.2 0.6 0.3
6.0 1.9 3.6 6.0 9.3 12.6 15.4 16.8 17.1 16.7 14.3 10.5 7.9 5.7 3.8 2.4 1.4 0.8 0.4 0.2
8.0 1.0 1.6 2.5 3.4 4.5 5.3 5.9 6.1 6.1 5.2 4.0 3.1 2.4 1.6 1.0 0.7 0.4 0.2 0.1
CIA
Y axis 0.0 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5
1.0 100.0 105.2 114.0 125.6 147.0
2.0 69.4 72.8 79.2 87.2 95.5 99.4
3.0 48.6 50.3 53.4 57.0 58.7 52.8 30.8 10.6
4.0 33.0 33.8 35.0 35.7 34.9 29.3 19.6 9.7 4.2
6.0 14.3 14.2 14.0 13.5 12.4 10.4 7.7 5.0 3.0 1.6
8.0 5.2 5.2 4.9 4.7 4.2 3.6 2.8 2.0 1.3 .08
CIB/CIB-2
X axis −8.5 −7.5 −6.5 −5.5 −4.5 −3.5 −2.5 −1.5 0.0 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5
1.0 164.7 145.6 135.4 125.0 100.0 41.2 19.0 9.6 5.2 2.7 1.5 0.9 0.4 0.2
2.0 139.1 125.2 115.1 104.4 94.1 71.6 39.5 22.6 12.3 6.8 3.6 2.0 1.0 0.5 0.3
3.0 121.0 107.3 96.9 86.6 77.9 68.7 52.4 32.8 20.7 12.6 7.4 4.0 2.2 1.1 0.6 0.3
4.0 93.0 86.2 78.3 70.7 63.7 56.7 49.8 37.7 24.9 17.3 10.9 6.5 3.9 2.1 1.1 0.5 0.3
6.0 22.8 30.8 34.8 34.8 33.2 30.7 27.3 23.9 18.3 12.9 9.3 6.5 4.1 2.5 1.5 0.8 0.5 0.2
8.0 8.6 11.1 12.6 13.5 13.2 12.5 11.3 9.7 7.5 5.4 3.9 2.8 1.9 1.3 0.7 0.4 0.2 0.1
CIB/CIB-2
Y axis 0.0 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5 10.5 11.5
1.0 100.0 107.1 118.3 132.1 155.0
2.0 71.6 76.5 84.3 95.9 109.2 126.7
3.0 52.4 55.5 60.7 68.5 78.7 91.1 108.3
4.0 37.7 39.8 43.3 48.0 55.1 62.6 72.6 83.4
6.0 18.3 19.1 20.2 22.1 24.3 26.0 26.6 24.5 17.8 9.5 3.1 0.9
8.0 7.5 8.1 8.3 9.0 9.3 9.6 9.2 8.0 6.3 4.1 2.4 1.2
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2.3.1 Planar plaque
The non–clinical planar plaque model CCB 570 was first used by Soares et al. (2001) and Cross
et al. (2001). Soares et al. (2001) compiled dose data measured using different detectors, differ-
ent materials and by different investigators to find a ‘best fit’ for all data that were available
at the time. No further experimental data for this plaque have been published since then.
The dataset included measurements conducted in water and plastic materials with extrapola-
tion chamber, radiochromic film, TLD 0.3 mm, TLD 1 mm, plastic scintillator, alanine detector
and diamond detector. Cross et al. (2001) performed simulations using the EGS4 (Kawrakow
et al., 2009) and ACCEPT 3.0 (Halbleib et al., 1992) codes and compared their results with
the available published data. Because the published calculations and measurements had been
conducted with different materials, they converted all dose distributions to dose–to–water
distributions using appropriate scaling factors. Those factors were obtained empirically as a
function of the effective atomic number of the medium, and of the relative stopping power
of the medium with respect to water (ICRU, 2004). This data processing procedure may have
added some uncertainty to the final results.
The depth–dose data from this work are more consistent with the published measure-
ments than the estimations using the EGS4 and ACCEPT 3.0 codes (Table 2.5). Although the
PENELOPE results exhibit the smallest difference at all depths, the differences for all codes are
below the measurement uncertainty, reported to be less than 10% (Cross et al., 2001). The
statistical uncertainties for the PENELOPE results were below 1% (k = 3). The uncertainties
of the results obtained with EGS4 and ACCEPT 3.0 were not reported, even though they are
suggested to be much lower than the measurement uncertainty (Cross et al., 2001).
TABLE 2.5: Differences in relative depth–doses estimated for the planar plaque with
respect to measurements among the estimations performed with the Monte Carlo
codes EGS4, ACCEPT 3.0, and PENELOPE.
Depth EGS ACCEPT 3.0 PENELOPE
(mm) [Cross et al. (2001)] [Cross et al. (2001)] [this work]
2.0 −3.7% −3.3% −1.3%
3.0 −4.5% −2.7% −1.5%
4.0 −3.3% −2.6% −1.2%
5.0 −3.4% −2.0% −0.8%
7.0 −1.5% −0.5% −0.2%
10.0 −0.8% −0.6% −0.4%
Lateral dose profiles at several depths of clinical interest were also estimated and com-
pared with the values provided by Cross et al. (2001) in Table I of their paper (see Figure 2.3).
The differences at the origin are a consequence of the differences in depth–doses shown in
Table 2.5. There are also some differences (of approximately 0.5 mm) in the distance of the
dose fall–off; this effect is specially remarkable at shallow depths: at a 1 mm depth, a 50%
dose value appears at approximately 10.5 mm in the Cross’ profile, whereas in this work, a
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FIGURE 2.3: Lateral profiles estimated in this work for a planar plaque, compared
with the profiles estimated by Cross et al. (2001). Profiles are normalized on the
central axis and at a depth of 1.0 mm. A better agreement is obtained in the lateral
dose fall–off distance when a diameter of 21.0 mm is used in the simulation.
50% dose value appears at approximately 10.0 mm from the central axis. Although Cross et al.
(2001) stated in the main text of their paper that the planar plaque had an active diameter of
20.5 mm, their Table I indicates an active diameter of 21 mm. To check if this difference in ac-
tive diameter could explain the discrepancy in the lateral profiles, a simulation was performed
assuming an active diameter of 21 mm, for which the dose fall–off distances were found to be
more consistent (see Figure 2.3). However, this 0.5 mm change in active diameter did not ap-
preciably affect the depth–dose distribution. The values tabulated in this work for the planar
plaque are provided assuming an active diameter of 20.5 mm.
Variations in the thickness of the exit window of ±10 µm respect to the nominal value
do not affect the result of the simulations. The differences in the depth–dose curve respect
to that obtained using the nominal value of 100 µm are within the attained relative standard
statistical uncertainty (0.3%).
The results obtained for the planar plaque validate the Monte Carlo simulation performed
with PENELOPE as a reliable method to estimate the absorbed dose distributions produced by
106Ru/106Rh ophthalmic plaques.
2.3.2 CCX/CCY/CCZ plaques
CCX/CCY/CCZ plaque models are designed for the treatment of retinoblastoma. Because
the only difference among these plaques is in the number and the position of the eyelets, the
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dose distribution is identical for all three models. Few data either experimental or simulated
on CCX plaques are available in the literature.
Kirov et al. (2005) used the 3D scintillation dosimetry method to measure the 3D dose dis-
tributions for two CCX plaques. The method relies on the observation of scintillation light
from an irradiated liquid scintillator volume, which acts simultaneously as a phantom mate-
rial and as a dose detector. Planar images are acquired at multiple angles to obtain the light
emission density in each voxel of the volume following tomographic reconstruction. The
dose values are approximately proportional to these density values. The 3D dose measure-
ments were compared against radiochromic film and diode measurements. A drawback of
this method is that the volume between the inner surface of the plaque and the distal edge
of the plaque cannot be measured because the plaque blocks the scintillation light. Unfortu-
nately, this ‘blocked’ volume is of most clinical interest because it is the closest volume to the
plaque. The stated uncertainty was∼25%, which is larger than the uncertainty reported using
other methods (Soares et al., 2001).
Fuss et al. (2011) simulated dose distributions for the CCX plaque using the LEPTS Monte
Carlo code. After comparing their results with published data for CCA (Sánchez-Reyes et al.,
1998) and CCB (Taccini et al., 1997; Cross et al., 2001) plaques, they concluded that the previous
works might have underestimated the dose in the low–dose region. However, the depth–dose
distributions estimated in this work indicate that Fuss et al. (2011) actually overestimated the
dose in the low–dose region by approximately 10–15% (see Figure 2.4), which most likely
occurred because of the marked differences in the beta spectrum used in their simulation
(experimentally determined) and the physical models implemented in their code.
The results presented in this thesis are in excellent agreement with the data provided in the
calibration certificates for three CCX plaques and with the depth–dose reference data from the
manufacturer. They are also compatible, within the experimental uncertainty, with the depth
dose measurements performed by Kirov et al. (2005).
Figure 2.5 shows a comparison of the PENELOPE lateral dose profile estimated at a 5.5 mm
depth with the experimental data measured at a 5.4 mm depth by Kirov et al. (2005). The
simulation results agree with the measurements within the experimental uncertainty (25%
for the 3D scintillator and 15% for the radiochromic film). The statistical uncertainty of the
simulated profile is below 0.3% (k = 3). The asymmetry in the experimental data may occur
because of a inhomogeneous distribution of the radioisotope in the measured plaque.
2.3.3 CXS plaque
The CXS and CCX plaques have an identical shape. The difference between them lies in their
active diameter, which is 9.5 mm for the CCX and 7.7 mm for the CXS plaque, as the latter
model is designed to treat retinoblastomas of small diameters and heights. Because there
are no published data for the CXS plaque, the estimated depth–dose distribution was only
compared with the manufacturer’s data, which were obtained with a plastic scintillator. The
difference in the relative doses was less than 1.3% [the statistical uncertainty was less than
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FIGURE 2.4: CCX depth–dose distribution estimated in this work compared with (a)
the experimental results reported by Kirov et al. (2005); (b) the data from the cal-
ibration certificates for three CCX plaques; (c) the reference depth–dose data from
the BEBIG user’s manual; and (d) the simulation results by Fuss et al. (2011) using
the code LEPTS. The results from PENELOPE simulations show good agreement with
the measurements performed by the manufacturer. Previous measurements appear
to overestimate these depth–dose values. The LEPTS simulation strongly overesti-
mates the depth–dose distribution for depths greater than 3 mm. Uncertainty bars
of PENELOPE data represent the statistical uncertainty with k = 3.
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FIGURE 2.5: Comparison of the CCX lateral profile estimated in this work with the
experimental results provided by Kirov et al. (2005). Dose distributions were nor-
malized at the central axis. Statistical uncertainty for simulated profiles is below
0.3% (k = 3). The stated uncertainties for the measurements by Kirov et al. are about
25% for the 3D scintillator, and 15% for the radiochromic film. Uncertainty bars are
not shown for clarity.
FIGURE 2.6: Relative isodose contours for the CXS plaque against the CCX plaque at
a plane containing the symmetry axis. The isodose lines for both plaque models are
normalized at a depth of 1 mm.
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0.5% (k = 3)]. Figure 2.6 shows a comparison of the simulated dose distributions produced
by CXS and CCX plaques at a plane containing the symmetry axis of the plaque, where the
effect of the greater active diameter of the CCX model on the isodose lines is shown.
2.3.4 CCC plaque
Only one paper provides results for the CCC plaque: Kovacˇevic´ et al. (2005) measured the
CCC depth–dose distribution with 1× 1× 1 mm3 TLD in a Plexiglas phantom and reported
a combined uncertainty of 6% (k = 1). They studied two plaques produced with a difference
of one year, designated as ‘old’ and ‘new’. Figure 2.7 shows a comparison of the present
work’s estimations with data from Kovacˇevic´ et al. (2005) and with the reference data from
the manufacturer. The results estimated with PENELOPE simulations agree within 3% with the
reference data from the manufacturer and with the data from the calibration certificate of the
‘new’ plaque of Kovacˇevic´ et al. (2005), whereas the difference reaches 10% with respect to the
TLD data.
2.3.5 CCD plaque
No published data are available for the CCD plaque. Hence, the results of this work could
only be compared with the depth–dose reference data obtained from the plaque’s manual. An
excellent agreement was observed (within 0.3%) for the data between depths of 0.5 mm and
10.0 mm. The statistical uncertainty of the simulation was better than 0.9% (k = 3).
2.3.6 CGD plaque
Only two references contain dose data for the CGD plaque. One is the work of Kaulich et al.
(2004), who analyzed the quality assurance procedures followed by the manufacturer in pro-
ducing the plaques. One criticism to the measurement system employed by the manufacturer
prior to 2001 was the large volume of the used scintillator (8 mm3). However, in 2001 BE-
BIG began to use a much smaller scintillator, of 0.4 mm3, with a calibration traceable to the
NIST. As part of their analysis, Kaulich et al. (2004) determined depth–dose curves using a
scintillator detector with a volume of 0.8 mm3 and compared their measurements with the
depth–dose data provided in the calibration certificate for a CGD plaque measured with the
manufacturer’s improved measurement system. The second reference is the work by Barbosa
et al. (2015), who designed a spherical phantom made of solid water with the dimensions of
the eye to measure the dose distributions with TLD at several depths. They reported standard
uncertainties of about 1.5% for the measured doses.
Depth–dose distributions simulated in this chapter are statistically compatible with the
reference data from the 2011 user’s manual for the plaque (Figure 2.8). However, the differ-
ence in the relative dose compared to the findings of Kaulich et al. (2004) is up to 3.5%. The
measurements conducted by the manufacturer prior to 2001 show a relative dose that is up
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FIGURE 2.7: CCC depth–dose distribution estimated in this work compared with
results by Kovacˇevic´ et al. (2005): (a) TLD measurements; (b) data provided in the
calibration certificates for two CCC plaques with production dates separated by one
year and designated as ‘old’ and ‘new’; and (c) the reference data from the manufac-
turer. The statistical uncertainty of the PENELOPE simulation results is less than 1.4%
(k = 3).
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FIGURE 2.8: CGD depth–dose curve estimated in this work compared with pub-
lished data. From the work by Kaulich et al. (2004): (a) measurements performed
using a scintillator of 0.8 mm3; (b) data from the calibration certificate (ASMW 1987)
measured with a scintillator of 8 mm3; and (c) data from the calibration certificate
measured with a scintillator of 0.4 mm3 (NIST 2001). From the work by Barbosa et al.
(2015), TLD measurements. Reference data from BEBIG manual is also included. The
statistical uncertainty of the PENELOPE simulation results is less than 1.2% (k = 3).
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FIGURE 2.9: Lateral dose distributions estimated with PENELOPE at depths of 1, 2,
3, 4, 6 and 8 mm along the X and Y axes for the asymmetric CIA plaque. The axes
convention is the same as the one shown on Figure 2.12 for the CIB/CIB–2 plaques.
Dose profiles are normalized at the central axis of the plaque, at a depth of 1 mm. The
statistical uncertainty of the PENELOPE simulation results is less than 0.8% (k = 3).
Uncertainty bars are not shown for clarity.
to 6% lower than the PENELOPE estimations and up to 9% lower than the measurements con-
ducted using small–volume scintillators. These observations might be explained by a dose–
averaging effect due to the large volume of the scintillator used by the manufacturer prior to
2001. Similar differences were observed with the measurements by Barbosa et al. (2015). The
maximum difference between their measurements and the simulations from this chapter is
about 4% at a depth of 4.3 mm.
2.3.7 CIA plaque
The CIA plaque is designed to treat ciliary body melanomas or melanomas close to the iris.
Because of this purpose, the plaque has an asymmetric shape with a cut–out section, which
increases the difficulty of measuring or calculating the dose distribution. This difficulty may
explain the lack of published data for this plaque. The relative depth–dose distribution es-
timated in this work was compatible within 1% (with a statistical uncertainty less than 0.7%
(k = 3)) with the reference data provided by the manufacturer. Figure 2.9 shows the asym-
metric lateral dose distributions obtained at several depths along the X and Y axes. The axes
convention is the same as the one shown on Figure 2.12 for the CIB/CIB–2 plaques.
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2.3.8 CIB/CIB–2 plaques
Similar to the CIA model, the CIB/CIB–2 plaques are designed to treat ciliary body mela-
nomas or melanomas close to the iris. However, the CIB/CIB–2 plaques have a larger diam-
eter and height than the CIA model. The only difference between the CIB and CIB–2 plaques
is the number and location of the eyelets. Hence, the dose distribution is identical for the
two models. The relative depth–dose distribution estimated with PENELOPE was compatible
within the statistical uncertainty with the reference data provided by the manufacturer. The
mean difference in the relative dose was 0.4% and the maximum difference was 3% at a depth
of 2.0 mm. The attained maximum relative statistical uncertainty was less than 1.0% (k = 3).
Figure 2.10 shows dose and statistical uncertainty maps for planes at several depths of inter-
est for the CIB plaque. The statistical uncertainties are similar to those obtained for the other
plaques. Figure 2.11 shows dose maps on planes parallel to the central axis, along the X axis.
For axes convention, see Figure 2.12.
In the only available study providing dose data on CIB plaques, Taccini et al. (1997) mea-
sured the dose distributions for a number of plaque models using radiochromic film. For the
CIB plaque they reported isodose contours at a plane perpendicular to the central axis at a
depth of 4.5 mm. Depth–dose data were not reported. A large discrepancy exists between the
planar dose distributions estimated in this work and those presented by Taccini et al. (1997)
(Figure 2.12). The shapes of the isodose lines are completely different and do not appear to
correspond to the shape of the CIB plaque. As Taccini et al. (1997) also examined a COB
plaque, which has a deeper cut–out than the CIB model, it is likely that the dose distribution
attributed to the CIB plaque actually corresponded to the COB plaque.
2.3.9 CCA plaque
The CCA plaque, together with the CCB, is one of the most commonly used plaques. It is
designed to treat mainly choroidal melanomas. Several references are available, including
Monte Carlo simulations (Davelaar et al., 1992; Sánchez-Reyes et al., 1998; Brualla et al., 2012,
2013, 2014; Barbosa et al., 2014) and measurements conducted with polymer gel (Chan et al.,
2001) and radiochromic film (Taccini et al., 1997; Heilemann et al., 2015). The depth–dose
curve estimated in this work was compared with the results from the previous references,
with the calibration certificates for three CCA plaques, and with the reference data provided
by the manufacturer. As shown in Figure 2.13 the results from the simulations carried out
in this work are compatible within the statistical uncertainty with the data from the calibra-
tion certificates and with the reference data provided by the manufacturer. However, large
discrepancies (∼15%) were observed compared to the early simulations conducted by Dave-
laar et al. (1992), which might be due to the approximations applied by the authors in their
physical models to reduce simulation time. Large differences were also noted compared to
the PENELOPE simulation by Sánchez-Reyes et al. (1998). Unfortunately, their study suffered
from important flaws (Brualla et al., 2012).
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FIGURE 2.10: Dose and statistical uncertainty maps for the CIB/CIB–2 plaque mod-
els at planes perpendicular to the central axis. Both, dose values and statistical un-
certainty values (k = 3) are normalized to the dose value (100%) of the bin centered
at (X, Y, Z)=(0, 0, 1) mm.
Chapter 2. Monte Carlo simulation of 106Ru/106Rh ophthalmic plaques 41
FIGURE 2.11: Dose maps for the CIB/CIB–2 plaque models at planes parallel to the
central axis. Doses are normalized to the dose value (100%) of the bin centered at
(X, Y, Z) = (0, 0, 1) mm. For axes conventions see Figure 2.12(c). It is apparent the
asymmetry of the dose distribution along the X axis due to the notched geometry of
the plaque.
FIGURE 2.12: Isodose lines for a CIB plaque in a horizontal plane at a 4.5 mm depth,
as (a) reported by Taccini et al. (1997), measured using radiochromic film, and (b)
estimated in this work using PENELOPE. Both dose distributions are normalized to
100% at a point in the central axis at a 2 mm depth. In (c), the geometrical forms of
the COB and CIB plaques are shown. It is likely that the dose distribution attributed
by Taccini et al. (1997) to the CIB plaque actually corresponds to the COB plaque.
The axes convention shown for the CIB plaque was used also for the CIB–2 and CIA
plaques.
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FIGURE 2.13: Depth–dose curve estimated in this work for the CCA plaque com-
pared with (a) measurements performed using radiochromic film (Taccini et al.,
1997); (b) measurements using polymer gel (Chan et al., 2001); (c) data from the cali-
bration certificates for three CCA plaques; (d) reference data from the manufacturer;
(e) Monte Carlo simulations by Davelaar et al. (1992); and (f) PENELOPE simulations
conducted by Sánchez-Reyes et al. (1998) and Brualla et al. (2013). The statistical un-
certainty of the PENELOPE simulation results in this work is less than 0.8% (k = 3).
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FIGURE 2.14: Lateral dose distributions estimated using PENELOPE at 1, 2, 3, 4, 6
and 8 mm depths for CCA (LEFT) and CCB (RIGHT) plaques. Dose profiles are
normalized at the central axis of each plaque, at a depth of 1 mm. The statistical
uncertainty (k = 3) is less than 0.8% for the CCA and less than 1.1% for the CCB
plaque. Uncertainty bars are now shown for clarity.
The agreement with the simulations performed by Brualla et al. (2012, 2013) using PENE-
LOPE is notably better, although a difference that is greater than the statistical uncertainty (less
than 1% in both cases) persists. For example, at a depth of 3 mm, the relative dose observed
by Brualla et al. (2013) is 58% and 55% in this work. This discrepancy may occur because
Brualla et al. (2013) set the diameter of the active area as 14.7 mm, whereas according to the
ICRU Report 72 (ICRU, 2004), the active diameter for CCA plaques is 13.0 mm, which is the
value used in this work. To test this hypothesis, an additional simulation was performed us-
ing an identical plaque geometry but with the active diameter set to 14.7 mm. This change
reduced the difference compared to Brualla et al. (2013, 2014) from 1.8% to 0.6% in the depth
range of 1–4 mm, but it increased the difference for greater depths from 0.3% to −1.2%. This
result suggests that another factor contributes to the differences between the depth–dose dis-
tribution estimated in this work and the results of Brualla et al. (2013). This factor may be
the different choices regarding the 106Rh beta spectrum. The spectrum used by Brualla and
coworkers was obtained by random sampling from the beta decay spectrum corresponding
to the disintegrations with the highest yields. To that purpose, they adapted the Fortran code
EFFY2 (García-Toraño and Grau-Malonda, 1985) which calculates the beta spectra applying
the Fermi theory of beta decay. The differences between the spectrum from the ICRU Report
72 used in this chapter and the spectrum obtained using EFFY2 were evaluated by compar-
ing the depth–dose curves obtained for the CCA plaque using both spectra as source for the
simulations, with the same geometry and simulation parameters. The mean difference in the
range 1–12 mm of depth was 0.5%, with a maximum difference of 1.5% at a depth of 2.5 mm.
Figure 2.14 (LEFT) shows the CCA lateral dose distributions at several depths simulated
in this work.
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Considering the improved agreement between the depth–dose distribution estimated in
this work and the available published experimental results, respect to previously published
works, the results presented here appear to represent the most reliable dataset for CCA plaques.
2.3.10 CCB plaque
For the CCB model there is an important lack of agreement among the published experi-
mental results. They agree only within 10%, so it is difficult to favor one result over the
others (Soares et al., 2001; Cross et al., 2001). Even larger differences are observed among the
published Monte Carlo simulation studies. Cross et al. (2001) presented the dose distribu-
tions computed using different Monte Carlo codes (ACCEPT 3.0, EGS4, MCNP4B, GEANT3
and the code from Davelaar et al. (1992)) for a CCB plaque, for which measurements were
also conducted by Soares et al. (2001). Unfortunately, a poor agreement was found among
the available simulations, and only the results of ACCEPT 3.0 agreed with the experimental
values.
Figure 2.15 (LEFT) shows the relative depth–dose distribution obtained in this work com-
pared to the published measurements. The results from this work agree with the experimental
values measured using scintillator detectors (Kaulich et al., 2005) and with the manufacturer’s
reference data for the CCB plaque model. In Figure 2.15 (RIGHT), the simulation results of this
work are compared with other Monte Carlo simulations provided in the literature. The pre-
sented results are statistically compatible with those of Brualla et al. (2013), which were also
obtained using the PENELOPE code. Although Sánchez-Reyes et al. (1998) also used PENE-
LOPE, their results are flawed (Brualla et al., 2012) and should be discarded. Figure 2.14
(RIGHT) shows the lateral dose distributions, tallied from the symmetry axis outwards, at
several depths.
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FIGURE 2.15: (LEFT) Relative depth–dose distribution obtained in this work compared with the published experimental data for the
CCB plaque. There is good agreement with the experimental values measured using scintillator detectors (Kaulich et al., 2005) and
with the manufacturer’s reference data. (RIGHT) Comparison with other simulation results provided in the literature. The present
results are in excellent agreement with those of Brualla et al. (2013) (within the statistical uncertainty), which were also estimated
using the PENELOPE code. Uncertainty bars of PENELOPE data from this work represent the statistical uncertainty with k = 3.
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2.3.11 Influence of the 106Pd gamma spectrum
Both 106Ru and 106Rh are pure beta emitters, that is, only beta particles are emitted when 106Ru
and 106Rh nuclei decay. 106Ru decays to the ground state of 106Rh. 106Rh nuclei decay with a
certain probability to excited states of 106Pd, which in turn deexcite emitting gamma rays of
discrete energy values (Defrenne and Negret, 2008). This gamma spectrum has been neglected
in all published studies on Monte Carlo simulation of 106Ru/106Rh plaques, as it was consid-
ered that its influence on the dose distributions was negligible. The previous simulations in
this chapter were performed also under this assumption to allow a comparison with previous
publications. This assumption, however, is an approximation that may bias the simulation
results and it was not justified quantitatively in any publication. Hence, a simulation study is
presented in this section to assess the influence of gamma rays from the 106Pd deexcitation on
the simulation of 106Ru/106Rh plaques.
The gamma energies were taken from Defrenne and Negret (2008). The gamma compo-
nents considered were those with energies above 10 keV and emission probabilities per disin-
tegration above 0.1% (Table 2.6). Apart from minor rounding differences, those are the same
energy values reported in the ICRU Report 72 (ICRU, 2004).
TABLE 2.6: Energy values and emission probabilities per disintegration of the
gamma components from the 106Pd transitions to the ground state included in the
simulations (those with Eγ > 10 keV and emission probability above 0.1%). Taken
from Defrenne and Negret (2008).
Eγ (keV) 511.86 616.22 621.93 873.49 1050.41 1128.07 1562.25
Emission probability
per disintegration (%) 20.0 0.75 9.93 0.439 1.56 0.404 0.163
To be consistent with the previous simulations of the chapter, the simulations from this
section were run with the same simulation parameters. Hence, to obtain low statistical un-
certainties at distances far from the plaque, an extremely long simulation time would result
(about 4–5 months using a single computing core). To overcome this unpractical computing
time a different approach was designed. The simulations from this section were run with
version 2014 of PENELOPE (Salvat, 2015a). To ensure that the change of version did not in-
troduce a bias in the results, the previous simulations for the plaques studied in this section
were rerun with PENELOPE 2014, confirming that the results were unaltered. PENELOPE 2014
includes a software tool, named penmain-sum, to combine the results of independent runs of
the same simulation problem allowing to use multiple computing cores simultaneously. Thus,
the efficiency of the simulation increases linearly with the available number of cores. Forty
cores were used to run each simulation in this section, reducing the simulation time to about
3 or 4 days per plaque, instead of about 4–5 months using a single core. Each independent
run produces a file with the partial results of the simulation with accumulated statistics (dump
file). The tool penmain-sum combines all dump files to get the final results of the simulation.
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FIGURE 2.16: Percentage depth–dose curves for the plaques CCA and CCC, showing
the effect of including in the simulations the gamma components produced by the
transitions to the ground state of 106Pd. Uncertainty bars represent the statistical
uncertainty with k = 3.
The process of manually generating the simulation files needed for multiple independent
runs is tedious, error–prone, and takes some time. To manage this situation efficiently, a soft-
ware tool was developed in this thesis consisting of a set of scripts written in MATLAB (The
MathWorks, Inc., Natick, MA, USA) which automate the process. Briefly, the scripts take care
of (i) creating the files needed for an arbitrary number of independent runs of the same simu-
lation problem; (ii) launching a number of independent simulation runs simultaneously; and
(iii) preparing the dump files to be combined with penmain-sum to obtain the final results of
the simulation. This software tool was named MUSIMAN (MUltiple SImulations MANage-
ment). The MATLAB source files and additional files of the MUSIMAN package are available
at the GitHub repository: https://github.com/marcelinohermida/MUSIMAN.
Figure 2.16 shows the percentage depth–dose curves for the plaques CCA and CCC, show-
ing the effect of including in the simulations the gamma components of 106Pd. The contribu-
tion of 106Pd gamma rays on the depth–dose curve is negligible at depths of clinical interest,
as it was assumed in the literature. The dose at distances about 24 mm from the surface of the
plaque is nearly 5 times greater when the gamma contribution is taken into account. At those
distances from the plaque, the dose is about 0.01%–0.1% of the dose at a depth of 1 mm. Thus,
those differences are not relevant for the clinical practice. However, for simulations involving
large distances from the plaques, such as for radiation shielding assessment and estimation of
dose received by personnel, this gamma contribution must be considered.
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2.3.12 Uncertainty analysis
The result of a calculation or a measurement is only meaningful if a quantitative statement of
its uncertainty is given. It is recommended to represent each component of the uncertainty by
an estimated standard deviation, named standard uncertainty. According to the method used,
the estimation of the uncertainty is classified as type A or type B (Bureau International des
Poids et Mesures, 2008):
• Type A evaluations of standard uncertainty: those which are evaluated by statistical
analysis of a series of repeated observations in the same conditions. For brevity, we will
refer to these uncertainties as type A uncertainties.
• Type B evaluations of standard uncertainty: those which are evaluated by other means
rather than statistical methods, evaluating all the information available, such as knowl-
edge on the performance of the equipment involved, specifications from the manufac-
turer, uncertainty values taken from available publications, etc. For brevity, we will refer
to these uncertainties as type B uncertainties.
The combined standard uncertainty of a result is assumed to represent the estimated standard
deviation of the result. It is obtained by combining the standard uncertainties from type A
and type B evaluations using the law of propagation of the uncertainty, that is, computing the
square root of the sum of the squares of each uncertainty contribution.
The results of Monte Carlo simulations are affected by both statistical (type A) and non–
statistical (type B) sources of uncertainty. The statistical uncertainty10 depends on the number
(N) of simulated histories as 1/
√
N. The number of histories in the simulations from this
chapter was large enough to ensure that the maximum value for the standard statistical un-
certainty of the estimated dose distributions was below 0.7%, and typically about 0.3%.
The two main sources of non–statistical uncertainty are:
• The approximation that the radioisotope is homogeneously distributed on the active
surface, although the actual distribution can vary greatly among plaques of the same
model. As an example, Eichmann et al. (2009) reported hot spots in the surface dose rate
of a CCB plaque of up to 18% respect to the dose at the center of the plaque. The purpose
of this thesis is providing data representative of each plaque model. Hence, to consider
the real radioisotope distribution of specific plaques goes beyond the objectives set.
• The modeling of the transport of radiation in PENELOPE, which includes uncertainties
due to the differential cross section data and to approximations in the transport and
material algorithms. The influence of those uncertainties in the tallied quantities have
never been systematically assessed. The physical models and interaction data included
in PENELOPE are the most accurate available up to date (Salvat, 2015b).
10 The term statistical uncertainty, although not formally defined by the Bureau International des Poids et
Mesures (2008), is of common use in the field of Monte Carlo simulation of radiation transport, and therefore
is also used throughout this thesis.
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Other sources of non–statistical uncertainty, whose contribution has been evaluated in the
thesis, include:
• The assumption that the silver exit window has a nominal thickness (100 µm), although
thickness variations of approximately 6 µm have been reported (Eichmann et al., 2009).
Simulations varying the exit window thickness in ±10 µm gave results compatible with
those obtained using the nominal thickness, within a standard statistical uncertainty of
0.3%.
• The modeling of the active layer as a mathematical surface. The thickness of the active
layer is only ∼0.1 µm. The previous item showed that variations up to ±10 µm in the
exit window thickness did not affect the simulation results. Thus, to assume an active
layer of zero thickness will not affect the results either.
• The lack of gamma contributions from 106Pd in the spectrum used as source for the
simulations. The results from section 2.3.11 confirmed that the effect of the gamma com-
ponents is negligible at depths of clinical interest, as it was assumed in the literature.
However, for other purposes such as shielding design or radiation protection of the
staff, the 106Pd gamma contributions should be included in the simulations.
These latter sources of uncertainty contribute to the overall uncertainty less than the at-
tained statistical uncertainty of the simulations.
An indication of the overall uncertainty can be obtained by comparing the Monte Carlo es-
timations with experimental results (ICRU, 2004). The depth–dose data estimated in this work
agree with most experimental data within 3% for all plaques. This value is consistent with the
ICRU Report 72 (ICRU, 2004) estimate of an overall standard uncertainty of approximately
3–4% for the Monte Carlo dose estimations for beta–ray sources.
50
Chapter 3
Absorbed–dose energy dependence of
the EBT3 radiochromic film
3.1 Introduction
The EBT3 radiochromic film model is the most recent model produced by Ashland for radio-
therapy applications. It is widely used for quality assurance in external beam radiotherapy
and brachytherapy. One frequently stated advantage of radiochromic films is an energy de-
pendence lower than that of the conventional radiographic films but the published results are
somewhat conflicting for photon energies below about 100 keV (Chiu-Tsao et al., 2005; Butson
et al., 2006; Rink et al., 2007; Sutherland and Rogers, 2010; Butson et al., 2010; Villarreal-Barajas
and Khan, 2014; Bekerat et al., 2014). The changes in the formulation of the active layers may
partially explain the discrepancy in the results of the energy dependence shown in previous
publications. At least three formulations for the active layer of the EBT3 film are described in
the literature, corresponding to different lots delivered under the same commercial denomi-
nation (Bekerat et al., 2014).
This chapter analyzes the energy dependence of the EBT3 radiochromic film with the lat-
est formulation through Monte Carlo simulations. The influence of the phantom material
in which the film is immersed during the irradiation is studied for a wide range of photon
energies. This topic has not been assessed in the literature. Several solid phantom materials
commonly used for film dosimetry are compared to water, the reference medium for radiation
dosimetry. These results will be used to assess a component of the experimental uncertainty
of the measurements presented in chapter 4. Moreover, the results have a wider scope, as
the EBT3 model is the current de facto standard for film dosimetry in radiotherapy and other
fields. The contents of this chapter were published by the author of this thesis and coauthors
in the Medical Physics journal (Hermida-López et al., 2014).
The general term beam quality refers to the energy distribution of a radiation beam, and it
is related to the penetrability of the beam in a material medium. In the case of monoenergetic
beams, the beam quality is established by the beam energy. For polyenergetic beams, the
beam quality relates to an index such as the beam mean energy, or the TPR20,10 (IAEA, 2001).
In what follows, to be consistent with previous publications (Sutherland and Rogers, 2010;
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Bekerat et al., 2014), we adopt the notation and terminology introduced by Rogers (2009) to
describe the characteristics of radiation dosimeters.
The energy dependence of a detector with the beam quality Q can be divided into two
components (Rogers, 2009): (1) the intrinsic energy dependence kbq(Q) with the beam quality
Q, which relates the dose absorbed in the sensitive component of the detector, Ddet(Q), with
the detector reading Mdet(Q):
Ddet(Q) = kbq(Q) Mdet(Q), (3.1)
and (2) the absorbed–dose energy dependence f (Q), which relates the dose absorbed in the
medium in the absence of the detector, Dmed(Q), with the dose absorbed in the sensitive
material of the detector Ddet(Q):
Dmed(Q) = f (Q) Ddet(Q). (3.2)
Another quantity of interest is the so–called absorbed–dose sensitivity, SAD,med(Q), defined as
the detector reading per unit of absorbed–dose to the medium estimated at the position of the
detector and in its absence, and as a function of the beam quality Q. For a radiochromic film
we can, for the purpose of this work, approximate the detector reading at beam quality Q as
the net optical density of the film, Mdet(Q) ≡ ∆ODdet(Q). The net optical density is defined
as the optical density change of irradiated films due only to radiation; corrections are made for
background optical density with a non–irradiated control piece of film. Then the absorbed–
dose sensitivity of a radiochromic film (or, less formally, the overall energy response), which
is a measurable quantity, can be expressed as follows:
SAD,med(Q) =
∆ODdet(Q)
Dmed(Q)
=
1
f (Q) kbq(Q)
. (3.3)
The absorbed–dose energy dependence f (Q) can be calculated through a Monte Carlo
simulation of radiation transport as, by definition, it only depends on the absorbed dose dis-
tribution in the medium and in the active layers of the film. To this purpose, an accurate
description of the geometry and material composition of the film layers is needed. The in-
trinsic energy dependence kbq(Q) is affected by chemical reactions on the film active layer
and by the film post–irradiation handling (scanner used, time delay between irradiation and
scanning, temperature of film storage, etc.), which are not modeled within the Monte Carlo
simulation of radiation transport. Notwithstanding, it can be be evaluated using equation
(3.3) by measuring the energy response of the film, SAD,med(Q), and then using Monte Carlo
simulations to calculate the absorbed-dose energy dependence f (Q).
Although water is the reference medium for radiation therapy dosimetry, for film dosime-
try it is more practical to use a solid phantom in some experimental situations, such as in the
calibration of films with a clinical electron linear accelerator. Since the composition of solid
phantoms differs from that of water, the energy response of the film may also differ.
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The definition of the absorbed-dose energy dependence f (Q) considers the absorbed dose
to the medium and the absorbed dose to the active element of the detector. If, instead of
considering the dose to the medium, we consider the quantity dose-to-water in the medium,
which is the common practice in radiation dosimetry, we could define a new quantity as the
‘absorbed-dose-to-water energy dependence’. Let us denote this quantity as:
g(Q) ≡ Dw,med(Q)
Ddet(Q)
, (3.4)
where Dw,med(Q) is the dose to a thin layer of water inside the medium, and Ddet(Q) is the
dose to the active element of the detector. We calculated this absorbed-dose-to-water energy
dependence, g(Q), for the phantom materials studied.
The Monte Carlo simulation work described in this chapter aims to study the influence of
plastic phantom materials respect to water on the absorbed-dose energy dependence of the
EBT3 radiochromic film, for photons in the energy range from 3 keV to 18 MeV. In addition
to monoenergetic photon beams, some theoretical X-ray spectra are used. To validate our
choice of simulation parameters, we also calculate f (Q) for older film models, EBT and EBT2,
comparing with published results (Sutherland and Rogers, 2010).
Only photons were included in this study as it was already established that the radio-
chromic films behave very similarly with electrons and photons (Sorriaux et al., 2013; Sipilä
et al., 2016).
3.2 Materials and methods
3.2.1 Radiochromic films and phantom materials
Figure 3.1 shows the layer structure of the radiochromic films studied in this chapter. The
EBT model has a symmetric 5–layer structure with two active layers 17 µm thick. The EBT2
model has an asymmetric structure with 5 layers, and only one active layer 30 µm thick to
increase sensitivity. The EBT3 film model is symmetric, with a single 30 µm thick active layer
sandwiched between two 125 µm polyester layers treated with microscopic silica particles to
avoid Newton rings. The silica particles were not included in the simulation as their effect
on the dose deposition is negligible (Bekerat et al., 2014). Table 3.1 shows the elemental com-
position by mass percent of the films simulated in this work. It should be emphasized that
the formulation for the EBT2 film shown on Table 3.1 is no longer produced, as well as the
EBT film. These discontinued formulations were used in our study for validation purposes
of the simulation setup allowing comparison with published data (Sutherland and Rogers,
2010). The formulation shown in Table 3.1 for the EBT3 film was the most recent at the time
of writing.
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polyester – 97 µm
polyester – 97 µm
active layer – 17 µm
active layer – 17 µm
surface layer – 6 µm
EBT EBT2
polyester – 50 µm
adhesive layer – 25 µm
topcoat layer – 5 µm
active layer – 30 µm
polyester – 175 µm
EBT3
polyester – 125 µm
polyester – 125 µm
active layer – 30 µm
FIGURE 3.1: Layer structure to scale of EBT, EBT2, and EBT3 films.
TABLE 3.1: Atomic composition by mass percent of the EBT [Sutherland and Rogers
(2010)], EBT2 [Sutherland and Rogers (2010)], and EBT3 (Ref: manufacturer, private
communication) films studied in this work. The composition of the active layers for
the EBT2 and the EBT3 has not changed since Oct. 2012 (Bekerat et al., 2014).
Atomic composition by mass percent
Layer C H O N Li Cl K Br Na S Al ρ(g/cm3)
Formulation
date
EBT Before2009
Active 57.4 9.4 16.4 13.2 0.8 2.9 - - - - - 1.10
Surface 32.3 6.5 20.5 21.6 2.3 16.8 - - - - - 1.20
Polyester 62.5 4.2 33.3 - - - - - - - - 1.35
EBT2 Feb.2009
Active
(lot #020609) 57.8 9.6 27.8 0.2 0.9 1.7 0.6 1.3 - - - 1.20
Adhesive 65.6 9.4 24.9 - - - - - - - - 1.20
Topcoat 47.2 8.8 38.2 - 1.0 4.9 - - - - - 1.20
Polyester 62.5 4.2 33.3 - - - - - - - - 1.35
EBT3 Dec.2013
Active 57.2 8.6 25.7 0.8 0.6 0.5 - - 0.4 0.3 5.8 1.35
Polyester 62.5 4.2 33.3 - - - - - - - - 1.35
Chapter 3. Absorbed–dose energy dependence of the EBT3 radiochromic film 54
We tested solid phantom materials commonly used for film dosimetry in the kV and MV
energy range: RW1 and RW3 (PTW-Freiburg, Freiburg, Germany), Solid Water (Gammex-
RMI, Madison, WI, USA) and polymethylmethacrylate (PMMA). Table 3.2 shows the corre-
sponding composition data.
TABLE 3.2: Atomic composition by mass percent of the phantom materials studied
in this work. The water density is stated at 20◦C and 101.3 kPa.
Water RW1 RW3 Solid Water PMMA
C - 79.4 90.4 67.2 59.98
H 11.2 13.2 7.6 8.1 8.05
O 88.8 3.8 0.8 19.9 31.96
N - - - 2.4 -
Ti - - 1.2 - -
Mg - 0.9 - - -
Cl - 2.7 - 0.1 -
Ca - - - 2.3 -
ρ (g/cm3) 0.998 0.970 1.045 1.036 1.190
Zeff 7.42 7.14 - 7.38 6.47
Ref. Sutherland and Rogers (2010) ICRU (1989) Hill et al. (2008) ICRU (1989) Hubbell and Seltzer (1996)
3.2.2 Simulation setup and PENELOPE simulation parameters
Simulations were run with PENELOPE 2011 (Baró et al., 1995; Salvat et al., 2011) using the
main program PENEASY (Sempau et al., 2011) (version 2012-06-01). The geometrical model
consisted of a cylindrical phantom with a radius of 20 cm and a thickness of 30 cm (Sutherland
and Rogers, 2010). Depending on the initial photon energy the film was positioned at different
depths taken from the work of Sutherland and Rogers (2010): (i) film laying over the surface
of the phantom for E ≤ 10 keV; (ii) with the upstream surface of the film at a depth of 1 cm
into the phantom for 10 keV < E ≤ 1.25 MeV; and (iii) with the upstream surface of the film
at a depth of 5 cm for E> 1.25 MeV.
Although the film extended over the entire radius of the cylinder, the dose scoring volume
consisted of the active layer of the film within a radius of 3 cm. In the simulations run to
evaluate the dose to the phantom, Dmed(Q), all film layers were replaced with the phantom
material, while the scoring volumes remained the same. In the simulations run to evaluate
the dose-to-water in the phantom, Dw,med(Q), all film layers were replaced with the phan-
tom material except the active layer which was replaced with water. The scoring volumes
remained the same.
We simulated monoenergetic parallel photon beams of 5 cm in diameter with energies in
the range 3 keV–18 MeV, and X-ray beams from an RT 100 superficial therapy system (C. H. F.
Müller; now Philips GmbH, Hamburg, Germany). The approximate X-ray spectra produced
by the RT 100 tube were modeled with the software SpekCalc (version 1.1) (Poludniowski
et al., 2009) which estimates the spectra emitted from tungsten anode X-ray tubes combin-
ing an analytical approach to model Bremsstrahlung production with Monte Carlo estimated
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target electron distributions. The simulated beams from the RT 100 had the following peak
kilovoltages [mean energies]: 30 kVp [17.6 keV], 45 kVp [24.3 keV], 55 kVp [28.5 keV], 85 kVp
[39.2 keV] and 100 kVp [45.0 keV]. The mean energies of the simulated beams were calculated
also with SpekCalc.
To validate our geometric and material model and to assess the adequacy of the chosen
PENELOPE simulation parameters we calculated f (Q) for the EBT and EBT2 film models,
comparing our results with those obtained by Sutherland and Rogers (2010) using the EGSnrc
Monte Carlo code (Kawrakow et al., 2009).
Simulation transport parameters were adjusted to obtain a nearly detailed simulation
in relevant regions and materials, such as the film layers and the phantom layers closer
to the film, while the transport parameters employed in the phantom volume far from the
film produce a simulation that deviates from a detailed one, to increase its efficiency in that
region. More precisely, for the film layers and the phantom layer above the film we set
C1 = C2 = 0.02. For the phantom layer downstream from the film up to 10 cm depth we
set C1 = C2 = 0.1, and for the phantom layer deeper than 10 cm we set C1 = C2 = 0.15.
WCC and WCR were set to 1 keV for all the simulation materials and DSMAX was set to one
tenth of the thickness of each layer, following recommendations from the PENELOPE man-
ual (Salvat et al., 2011). For some test cases we verified that the results obtained with the
chosen simulation parameters were statistically compatible to those obtained using detailed
simulations. In this manner, we reduced the calculation time without compromising the accu-
racy of the results. For electrons and positrons the absorption energies in the film layers were
set to 0.1 keV for initial energies below 3 MeV, and to 1 keV for higher energies. For photons
the absorption energies in the film layers were set to 0.1 keV. The standard statistical uncer-
tainty attained was below 0.7% for 75% of the calculated values and never exceeded 1.4%. All
statistical uncertainties in this chapter are reported to one standard deviation.
3.3 Results and discussion
3.3.1 Validation of simulation parameters: f (Q) for the EBT and EBT2 films
Our calculated f (Q) values for the EBT and EBT2 films agree within 2% with published
data (Sutherland and Rogers, 2010) calculated with the EGSnrc Monte Carlo code (Figure 3.2),
except for some data points at photon energies around 10 keV for the EBT2 film. To verify
if the different absorption energies used in our work (0.1 keV) and those used in the Suther-
land and Rogers paper (1 keV) could be the cause of the discrepancies at energies lower than
10 keV, we ran additional simulations with an absorption energy of 1 keV. We found that
the differences in f (Q) were within the statistical uncertainty (below 0.8%). So, the different
absorption energies cannot explain the differences found between our work and the work by
Sutherland and Rogers (2010) for the EBT2 film at low energies. As the EBT2 film has an asym-
metric layer structure, we also studied if the orientation of the film had some influence in the
absorbed-dose energy dependence in water. We ran simulations with the film upside down
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FIGURE 3.2: Calculated absorbed-dose energy dependence f (Q) in water for EBT
and EBT2 (lot #020609) films compared to Sutherland and Rogers (2010) results.
Lines are a visual aid to connect data points from the work of Sutherland and Rogers.
For clarity, the data points from this work are not connected with lines. The standard
statistical uncertainty bars are smaller than the symbols size.
and the difference in f (Q) found between both orientations was within the standard statisti-
cal uncertainty reached, below 1%, except for the lowest simulated energy (5 keV), where the
difference was of −3.5%.
3.3.2 Absorbed-dose-to-water energy dependence g(Q) of EBT3 film: influence of
the phantom material
Figure 3.3 shows the calculated g(Q) for the EBT3 film for the phantom materials used. In the
photon energy range from 10 keV to 18 MeV, the f (Q) for water was constant within 2.3%,
with a standard statistical uncertainty less than 1%. This result represents an improvement
of EBT3 film with respect to the older EBT2 film which showed a marked energy dependence
(Figure 3.2). If we consider the quantity dose-to-water in the phantom, then the difference
in energy dependence for the solid phantoms with respect to water is within 6% for energies
above 10 keV. The g(Q) values obtained for the mean energies of the X-ray beams tested are
very similar, as expected, to the values found for the corresponding monoenergetic beams,
with differences below 2% for Solid Water, RW1, RW3, and PMMA and below 0.7% for water.
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FIGURE 3.3: Calculated EBT3 film absorbed-dose-to-water energy dependence g(Q)
as a function of the phantom material used, when considering the quantity dose-to-
water in the phantom material. Note that, for water, g(Q) = f (Q), by definition. The
X–ray beams (kVp beams) are represented in the graph with their mean energies.
The standard statistical uncertainty bars (k = 1) are smaller than the symbols size.
3.3.3 Discussion
We calculated the influence of the phantom material in which the film is located on the ab-
sorbed dose energy dependence for the EBT3 film, considering the quantity dose-to-water in
the phantom, Dw,med(Q). As long as we calibrate the film in terms of absorbed-dose-to-water,
there is only a small influence of the phantom material on the energy dependence of the film
between 10 keV and 200 keV, and practically no influence for energies above 200 keV.
The absorbed-dose energy dependence does not explain all the energy response of the film,
as the intrinsic dependence kbq(Q) must also be considered. The intrinsic energy dependence
is related to the polymerizing efficiency in the active layers of the film, but it also depends
on the post-irradiation handling of the film. Figure 3.4 shows, for the EBT3 film in water, the
measured overall energy dependence S−1AD,w(Q) taken from Figure 12 of Bekerat et al. (2014),
the absorbed-dose energy dependence f (Q) calculated in this work, and the intrinsic energy
dependence kbq(Q) derived using equation (3.3).
We used the latest formulation of the EBT3 film available from the manufacturer in De-
cember 2013, with 5.8% Al (see Table 3.1). Bekerat et al. (2014) stated that the studied film
contained 7% Al, but they did not state the complete atomic composition. We made additional
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FIGURE 3.4: EBT3 film energy dependence in water: overall energy response
S−1AD,w(Q) measured by Bekerat et al. (2014), absorbed-dose energy dependence f (Q)
calculated with PENELOPE in this work (using 5.8% and 7% aluminum content), and
intrinsic energy dependence kbq(Q) derived from equation (3.3). The uncertainty
bars represent the standard statistical uncertainty.
simulations considering an EBT3 film with 7% Al and assuming that the other components of
the formulation were reduced proportionally. This means that the 7% Al composition used in
this work is not necessarily the same as the 7% Al composition from Bekerat et al. (2014). The
standard statistical uncertainty of the results was below 1%. Both curves for the f (Q) (5.8% Al
and 7% Al) are compatible, confirming that the small difference in aluminum content between
both formulations has a negligible effect on f (Q) at the statistical uncertainty reached.
The comparison of the results of the simulation of monoenergetic beams with measure-
ments obtained with polyenergetic spectra is an approximation. Within this approximation,
the reported overall energy response in water of the EBT3 film at low energies turns out to be
mainly due to the intrinsic energy dependence.
The EBT3 film shows a reasonably constant absorbed-dose energy dependence when ir-
radiated in water. If we consider the quantity dose-to-water in the phantom, the maximum
difference of EBT3 energy dependence with the solid phantoms studied respect to water is
about 6%, found at an energy of 50 keV. Moreover, the reported overall energy dependence
of the EBT3 film in water at energies below 100 keV is mainly due to the intrinsic energy
dependence.
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Chapter 4
Measurement of absorbed dose
distributions from 106Ru/106Rh plaques
with the EBT3 radiochromic film
4.1 Introduction
This chapter presents a practical method developed in this thesis for measuring in water the
2D absorbed dose distributions and the absolute dose rates produced by 106Ru/106Rh oph-
thalmic plaques. Two plaques of the CCX model (CCX 228 and CCX 250) and one plaque of
the CCA model (CCA 1440) were studied, whose physical dosimetry was analyzed in chap-
ter 2. The measurements were made using the EBT3 radiochromic film studied in chapter 3.
Two experimental setups were developed to measure the dose distributions with the film and
the plaque immersed in water: one to measure the 2D dose distribution at the plane Z=5 mm,
perpendicular to the symmetry axis of the plaque, and another to measure the 2D dose distri-
bution in the XZ plane (PDD plane). The main advantage of measuring in water is avoiding
the conversion from dose–to–plastic to dose–to–water and the associated uncertainties. At the
time of this writing all reported measurements of 106Ru/106Rh plaques with radiochromic film
were done using plastic phantoms (ICRU, 2004; Soares et al., 2001; Taccini et al., 1997; Heile-
mann et al., 2015). Another advantage of the experimental method presented in this chapter
is that it uses equipment and tools easily available at any medical physics department from a
hospital with external beam radiotherapy facilities.
The following sections explain the experimental setups, film calibration and processing,
analysis of the results, and comparison to the Monte Carlo simulation results shown in chap-
ter 2, and with the available results in the literature.
4.2 Materials and methods
4.2.1 Experimental setups
A mold was made for each plaque model to obtain a positioning of the plaque as accurate
as possible. Using dummy plaques (plaques with the same geometrical dimensions as the
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FIGURE 4.1: Mold made with polymer clay using the dummy plaque (indicated by
the small hole) of the CCX model.
clinical plaques, but with no radioisotope layer), the molds were made (Figure 4.1) with a
commercially available polymer clay (Sculpey, Polyform Products Company, USA). It has a
texture similar to plasteline, and it is hardened in a conventional oven during 15 min at 130°.
Setup for measurements at a plane perpendicular to the symmetry axis
Figure 4.2 shows the setup used to measure the dose distribution at a plane perpendicular to
the symmetry axis of the plaque. The measurements were done at 5 mm from the intersection
point of the symmetry axis and the inner surface of the plaque. From now on, this distance
will be referred to as the ‘film–plaque distance’. To achieve an easy centering and alignment
the setup was mounted on the treatment couch of a radiotherapy linear accelerator to take
profit of the zenithal perpendicular laser beams installed on the ceiling of the treatment room.
The set of mold–plaque–film was introduced in a small PMMA tank filled with distilled water.
The tank was on a leveling support. An auxiliary plastic box filled with water was used to
transport the plaque from/to the measurement tank and the handling area, situated behind a
15 mm PMMA shielding. The plaque was handled with tweezers at all times. The pieces of
film used for this setup, of about 50× 50 mm2 were cut with the help of a paper template and
fixed with paper tape to the top face of a Roos chamber adapter [Figure 4.2(b)], which was
found to have adequate dimensions for these measurements.
The mold with the plaque was introduced in the water tank and aligned with the laser
beams. Then, a set of PMMA spacers 8.5 mm thick was located on both sides of the mold
and on its caudal side [Figure 4.2(d) and (e)]. The Roos adapter with the film was finally set
on the spacers, thus being 5 mm the distance from the plaque’s surface to the film. In this
setup, the final film positioning was achieved in about 10 s, with measuring times from 60
to 120 min. Hence, the contribution of the positioning to the dose uncertainty is below 0.3%.
After measuring, the films were removed, dried, labeled and stored in a black envelope until
they were scanned.
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FIGURE 4.2: Experimental setup for measurement of perpendicular dose planes at
a film–plaque distance of 5 mm. (a) General view of the setup. 1: Water tank; 2:
Leveling platform with circular bubble level included; 3: PMMA shielding for safe
handling of the plaque. The blue box, next to the water tank, was filled with wa-
ter and used for radiation protection purposes, to transport the plaque from/to the
measurement tank and the handling area behind the shielding. (b) Film fixed to film
support (a Roos chamber adapter). (c) Perpendicular green laser beams installed on
the ceiling of the treatment room were used to ensure proper centering and align-
ment of the plaque (CCA in the picture) and the film. (d) Lateral view of CCX setup,
showing the spacers needed to put the film at 5 mm from the surface of the plaque.
(e) Detail of the setup for the CCX plaque. Film and plaque alignment checked with
the ceiling laser. (f) Sample of film irradiated with this setup. The dark rim (about
2–2.5 mm) near the edge of the film was caused by water penetration, which does
not affect the measurement area.
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Setup for PDD measurement
Figure 4.3 shows the setup for PDD measurements. A standard water tank (MED–TEC) was
used to contain the set of mold–plaque–film immersed in water. Distilled water was used to
avoid lime stains on the film due to long measuring times (several hours). A PMMA base
was used to support the mold with the plaque. Both the water tank and the PMMA base
were leveled before measuring. The mold with the plaque was centered and aligned with the
help of a laser level. The pieces of EBT3 film, of about 70× 30 mm2, were cut following the
spherical form of the plaque with the help of a paper template. A thin layer of nail polish was
applied to the film edges in contact with the plaque to avoid water penetration (Heilemann
et al., 2015). With these precautions, only the first 1–1.5 mm from the film edge needed to be
discarded from the dosimetric analysis.
The upper part of the film was tightly sandwiched between PMMA plates of 30× 30×
3 mm3. The lateral position of the vertical movement device of the water tank (see Figure 4.3,
(a)2), indicated by a scale on the side of the tank, was annotated. The device was then removed
from the tank and the sandwiched film was attached to the device with adhesive tape (see
Figure 4.3, (a)4, and (b)–(d)). Once the mold with the plaque was correctly centered the device
with the attached film was repositioned at the original position in the water tank and the
film was vertically moved until the film contacted the inner surface of the plaque. With some
practice, this final film positioning can be accurately done in less than a minute, reducing
the uncertainty in film dose due to film irradiation during the positioning. As the irradiation
time was about 150 min, the uncertainty associated with dose absorbed by the film during
positioning is less than 0.7%. At the end of the measurement the films were removed, dried,
labeled and stored in a black envelope until they were scanned.
4.2.2 Film calibration and reading
Film calibration and reading was made following the recommendations of the manufacturer
and those found in literature (Blackwell et al., 1998; Devic, 2011; Devic et al., 2016). The
changes in the film color when irradiated are due to a polymerization process in which needle–
like polymers grow preferentially along one direction. Rotation of the irradiated films on the
scanner bed can give differences in the measured signal as high as 8% (Devic et al., 2016).
Hence, the same orientation of the films was maintained at all steps of the experimental pro-
cedure. Films used corresponded to the same lot (#06051403). Films were handled with gloves
during film preparation, calibration, measuring and scanning.
For calibration, films were cut into strips of 42× 203 mm2 and irradiated in a 6 MV pho-
ton beam from a Clinac 2100 clinical electron linear accelerator (Varian Medical Systems,
Palo Alto, CA, USA). The linear accelerator absorbed dose to water in reference conditions
was determined according to the International Atomic Energy Agency TRS–398 code of prac-
tice (IAEA, 2001). Output calibration was done in a water phantom using a cylindrical ioniza-
tion chamber type TM30013 and an UNIDOS webline T10021 electrometer, both manufactured
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FIGURE 4.3: Experimental setup for measurement at the PDD dose planes. The
whole system was leveled before measuring. Water level was about 60 mm above
the plaque surface. (a) General view of the setup– 1: Water tank, 2: Screw device
that allows to manually move the film support in the vertical axis with precision of
0.1 mm, 3: Laser level to check the alignment of the film and the plaque, 4: Appli-
cator in the mold, and film in measuring position. (b) Sagittal view. (c) Lateral view
with vertical laser beam parallel to the film edge. (d) Alignment of the film and the
plaque checked with laser level. (e) Sample of film irradiated with this setup.
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by PTW (Freiburg, Germany). The chamber–electrometer set was calibrated in absorbed dose
to water in 2014 at the PTW secondary laboratory, which is traceable to the Physikalisch–
Technische Bundesanstalt. For the absorbed dose measurement in reference conditions, the
center of the chamber was located at 100 cm from the radiation source of the accelerator, at a
depth of 10 cm in the water phantom. A square radiation field of side 10 cm was used.
Although the measurements of the 106Ru/106Rh plaques were carried out in water, for
convenience the calibration films were irradiated in a PMMA phantom composed by plates
of 300× 300× 10 mm3. The films were set at a depth of 50 mm in the phantom. The distance
between the radiation source from the accelerator and the films was 100 cm. The films were
irradiated with a square radiation field of side 20 cm. Ten centimeters of PMMA were inserted
under the film for backscattering purposes. Nine strips were used. One of the strips was not
irradiated and the others were irradiated from 0.2 Gy to 30 Gy. The monitor units needed
to give the desired doses to the film were calculated with the Varian Eclipse 11.0 treatment
planning system, on a CT scan of the PMMA phantom. The accuracy of the Eclipse calculation
was checked by measuring the dose inside the PMMA phantom with the ionization chamber
into a PMMA plate. The differences found were within 0.3%. The elapsed time between the
irradiation of the first and the last calibration film was 1 h. The films were stored in a black
envelope until the scanning process.
The calibration and measurement films were read 19 h after exposure in an Expression
10000XL flatbed scanner (Seiko Epson Corporation, Nagano, Japan). A resolution of 72 dpi
(0.353 mm/pixel) and 16 bits per color channel were used, according to the recommendations
of the manufacturer. That is, the color level for each channel (red, green and blue) is repre-
sented using 216 = 65536 discrete values. A higher resolution of 150 dpi was tested but it
was discarded as the calibration uncertainty increased due to noise in the image. The scanner
was warmed up for at least 120 min before the scanning process. The calibration strips were
scanned all at once in the same scan to avoid the uncertainty associated with interscan vari-
ations. One possible source of uncertainty in film scanning is bending of the film, specially
for small pieces. To avoid bending, a glass plate was positioned over the film in the scanner
surface, for both the calibration and measurement films.
The usual method for radiochromic film dosimetry has been based on information ex-
tracted from a single color channel, assigning a dose to each color level. As a result, any
color disturbances on the image, such as those due to film thickness variations or other ar-
tifacts, are transformed into dose variations from the true dose value (Devic, 2011). Micke
et al. (2011) proposed the first triple–channel method to take profit of the different responses
of the film components to irradiation: whereas the red channel response is dominated by the
active layer of the film, the blue channel response is dominated by the presence of the yellow
marker dye incorporated to the film11. They modeled the scanned optical density distribu-
tion as a product of two factors: a dose–dependent factor, which is the true dose map, and a
11 The green channel is also sensitive to irradiation, but it is more sensitive to doses above 10 Gy, whereas the
red channel is more sensitive to lower doses such as those used in this work.
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dose–independent perturbation. By minimizing the differences in the dose obtained from the
different color channels, the dose–independent contribution can be derived. In this way, the
method removes the effect of film non–uniformities and thickness variations, scanner artifacts,
and other disturbances on the measured dose distributions. This method was implemented
by the film manufacturer in the film analysis software FilmQA Pro 2015, which was used to
obtain the measured dose distributions presented in this chapter.
The scanned calibration films saved in TIFF format were imported into FilmQA Pro 2015
software. For each calibration strip, a region of interest (ROI) was defined at the central part of
the film. The average of the color levels inside the ROI was correlated with the corresponding
dose to the film. Then, a fit for the color level X (rescaled to discrete values between 0 and 1)
against the dose D (in Gy) was made for each color channel, using rational functions of the
form X(D) = a + b/(D + c). This type of rational functions is a convenient choice as they
need only three fit parameters, which means that with a small number of calibration films it is
possible to obtain an accurate fit valid for a wide dose range. Moreover, rational functions are
monotonic, matching the physical response of the film better than polynomials (Micke et al.,
2011). Figure 4.4 shows the calibration curve obtained in this work for each color channel,
and Table 4.1 shows the fit parameters with the corresponding standard uncertainties. For
the range of doses used in this work (below 8 Gy), the red channel shows the most sensitive
response. Hence, all dose distributions from the films were obtained using the calibration for
the red channel.
TABLE 4.1: Fit parameters with standard uncertainties for the calibration curve of
each color channel. The sum of squared residuals (χ2) shows the goodness of the
fits.
Red Green Blue
a (45.957± 2.663)× 10−3 (−6.4180± 5.437)× 10−3 (46.845± 5.822)× 10−3
b 1.7695± 0.0329 3.9848± 0.1255 4.1988± 0.2392
c 3.0354± 0.04927 6.3983± 0.1624 12.767± 0.5411
χ2 3.796× 10−5 5.886× 10−5 2.240× 10−5
4.2.3 Evaluation of measured dose distributions
The experimental results were obtained for the 2D dose distributions at the XZ plane, which
contains the symmetry axis (Z axis) of the plaque (PDD plane), and for the 2D dose distribu-
tions at a plane perpendicular to the symmetry axis at a film–plaque distance of 5 mm. The
measured dose distributions were compared to the Monte Carlo simulation results presented
in chapter 2. Also, absolute dose rate values were extracted from the measured films and com-
pared to the values stated in the calibration certificates provided by the manufacturer, which
are traceable to the NIST.
After the scanned films were processed with the FilmQA software to obtain 2D dose maps,
ROIs were selected on relevant areas of the scanned films and the dose matrices were exported
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FIGURE 4.4: EBT3 dose calibration functions relating color level (at 16 bits per color
channel, that is, the color level is represented using 216 = 65536 discrete values) and
absorbed dose given to calibration film strips. The data points were fit to a rational
function X(D) = a + b/(D + c), with X being the color level rescaled to values
between 0 and 1, and D the absorbed dose.
to be further analyzed with MATLAB. When comparing 2D dose distributions in this work,
the first step was to register the dose distributions to be compared. Image registration consists
of aligning the same features in images collected in different situations or with different image
modalities (Crum et al., 2004). It involves applying geometric transformations to an image to
minimize the differences respect to another (reference) image. Only rigid transformations
were applied (i.e. shifts and rotations) to correct minor misalignments and rotations occurred
during the measurement and the scanning process.
The measured dose distributions were normalized as follows. The PDD dose planes were
normalized to the dose of the bin located at 2 mm from the film edge along the symmetry
axis of the plaque. For the perpendicular dose planes, the normalization was done respect
to the value of the central bin of the dose distribution. The geometrical center of this bin
corresponds to the point of intersection between the symmetry axis of the plaque and the
film. All comparisons of 2D dose distributions presented in this chapter are made between
normalized dose distributions.
The agreement between the 2D dose distributions (measured against measured, and mea-
sured against simulated) was assessed through the gamma index (Low et al., 1998), commonly
used to evaluate dose distributions in radiotherapy. The simplest metric to compare two dose
distributions is the dose difference. This is adequate in low dose–gradient regions, but in
regions of high dose–gradient, a small spatial error in the calculation or the measurement
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may produce a high dose difference. For these high dose–gradient regions, the distance–to–
agreement (DTA) is a more adequate metric. The DTA is defined as the distance between
a data point from the reference dose distribution and the nearest point in the evaluated dose
distribution with the same dose. The gamma index combines the dose difference and the DTA
into a single metric. When an evaluated dose distribution De(~re) is compared to a reference
dose distribution Dr(~rr), the dose difference is
δ(~re,~rr) = De(~re)− Dr(~rr), (4.1)
and the distance between the point ~re in the evaluated distribution and the point ~rr in the
reference distribution is
r(~re,~rr) = |~re − ~rr|. (4.2)
If ∆D and ∆r are the acceptance criteria for the dose difference and the DTA, respectively, the
gamma index at the reference point ~rr is then defined as
γ(~rr) = min

√(
δ(~re,~rr)
∆D
)2
+
(
r(~re,~rr)
∆r
)2 ∀ {~re} , (4.3)
where the expression in braces is computed for a set of points {~re} for each reference point
~rr. In this work, the set of points {~re} are those within a distance of three times the DTA cri-
terion (Wendling et al., 2007). The global gamma index was used, that is, the dose difference
percentage is referred to the maximum dose of the reference dose distribution. The bins in-
cluded in the gamma analysis were those with doses greater than 10% of the maximum dose
of the reference dose distribution. This percentage is the so–called dose threshold. As com-
mented in chapter 2, in the simulations the bins that cross the interface between the plaque
and the water phantom are subject to a partial–volume effect. To avoid a bias in the compari-
son results due to this effect, the involved bins were not included in the gamma analysis.
For each comparison, the percentage of agreement is reported, which is the percentage
of evaluated bins with gamma index less than unity. We consider that an acceptable agree-
ment is obtained for given gamma criteria if the percentage of agreement is above 90%. The
statistical fluctuations inherent to simulated dose distributions affect the gamma evaluation,
underestimating the average gamma index, and therefore overestimating the percentage of
agreement (Graves et al., 2013). The effect reduces if the statistical uncertainty of the simula-
tions is low, such as in the results presented in chapter 2 (with standard statistical uncertainties
typically below 0.3%). The MATLAB routine to compute the gamma index was taken from
the work of Scherman (2009), with permission from the author.
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4.3 Results and discussion
4.3.1 Absolute dose rate
Table 4.2 shows the measured dose rates extracted from the PDD films (at 2 and 5 mm deep)
for the CCA 1440 and CCX 228 plaques, and from the perpendicular dose plane at a film–
plaque distance of 5 mm for the CCX 250 plaque. The doses reported for the CCA 1440 are
the average of two measurements. The doses reported for the CCX 228 and the CCX 250 were
obtained from the only available measurement for each plaque. The doses from BEBIG were
taken from the calibration certificates provided with the plaques, which report a standard
uncertainty of 10%. The measured dose rate agrees with the values stated in the certificates
within the experimental uncertainties.
TABLE 4.2: Measured absolute dose rate values compared with the values stated in
the calibration certificates of the plaques provided by BEBIG, corrected by decay to
the date of measurement. The stated standard uncertainty values are derived from
the uncertainty analysis of section 4.3.4.
CCA 1440
PDD
CCX 228
PDD
CCX 250
axial plane
z = 2 mm z = 5 mm z = 2 mm z = 5 mm z = 5 mm
Measured
(mGy/min) 20.49±1.52 7.40±0.55 26.64±1.97 7.39±0.55 17.81±0.68
BEBIG
(mGy/min) 22.86±2.29 7.73±0.77 26.25±2.63 7.09±0.71 17.08±1.71
Relative difference
(meas.–BEBIG) −11.57% −4.46% 1.46% 4.06% 4.10%
4.3.2 Dose plane perpendicular to the symmetry axis at a film–plaque distance of
5 mm
To evaluate the setup uncertainty, three independent measurements with the CCA 1440 plaque
were done (Figure 4.5). The irradiation time (2 h) was the same for the three films. The
arithmetic mean of corresponding bins in the dose matrix of the measured distributions was
computed to obtain an average measured dose distribution. Each measured distribution was
then compared to this average distribution using the gamma index. For gamma criteria of
3%/0.5 mm (acceptance criterion of 3% for the dose difference, and of 0.5 mm for the DTA),
the percentage of agreement was 97.8%. This result suggests that the uncertainty associated
to the measurement repeteability is better than 3% and 0.5 mm. The measured distributions
showed an inhomogeneity region consistent with the information provided in the calibration
certificate of this particular plaque.
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FIGURE 4.5: Repeteability of the setup to measure dose planes perpendicular to the
symmetry axis for the CCA 1440 plaque. (a)–(c): Measured absolute dose distribu-
tions at an axial plane at a depth of 5 mm from the plaque surface, for three inde-
pendent measurements of the CCA 1440 plaque. (d)–(f): Comparison of each mea-
sured distribution (‘Film dose’ in the graphs) with the average dose distribution, for
registered dose distributions using a rigid transformation (i.e. shifts and rotations).
(g)–(i): γ index maps for each measured distribution against the average dose dis-
tribution, which was the reference set for the gamma index analysis. The values for
the percentage of agreement yielded by the γ index analysis were, from left to right,
100.0%, 100.0% and 97.9%, for γ criteria of 3%/0.5 mm.
Chapter 4. Measurement of dose distributions produced by 106Ru/106Rh plaques 70
Figure 4.6 shows the comparison of the average measured dose distribution for the CCA
1440 plaque against the corresponding results from the Monte Carlo simulation. Both pla-
nar distributions were normalized to the value of the central bin, and were registered with
a rigid transformation. The disagreement found is consistent with the inhomogeneity of the
radioisotope distribution of this particular plaque, as the simulations from this work assumed
that the radioisotope was homogeneously distributed on the active layer. With gamma criteria
of 3%/0.5 mm the agreement is poor, only 68.3%. To obtain an acceptable agreement (above
90%), the gamma criteria need to be relaxed up to 6%/1 mm.
For the CCX model, two plaques were measured, CCX 228 and CCX 250, to investigate
differences in source inhomogeneity among plaques of this model. Figure 4.7 shows the
good agreement obtained with percentages of agreement above 99% for gamma criteria of
3%/0.5 mm.
Figure 4.8 shows the comparison of the average measured dose distribution for CCX
plaques compared to the simulation results. Although there is a good agreement between
measurements and simulation results in the central region, there is a remarkable disagree-
ment at the edges of the dose distribution in the region around the isodose line of 10%, with
differences of about 6% relative to the dose maximum, which could be explained by an in-
homogeneous distribution of the radioisotope near the edges of the studied CCX plaques.
The calibration certificates provided by the manufacturer include measurements made with
a plastic scintillator at points located at 1 mm from the plaque’s inner surface, and at several
positions from the axis to 5 mm beyond the edge of the plaque. Figure 4.9 shows radial aver-
ages of these measurements for the plaques studied in this work. The dose at 5 mm outside
the edge is about 60% greater for the CCX 228 and the CCX 250 plaques, than for the CCA
1440 plaque. These data are consistent with the measurements from this work.
Dose profiles along the X axis were extracted from the average measured dose distribu-
tions for both plaque models and were compared with the corresponding profiles from the
Monte Carlo simulations and with the available published data (Figure 4.10). The asymmetry
of the measured dose profile for the CCA 1140 plaque is due to an inhomogeneous radioiso-
tope distribution (see Figure 4.5). The discrepancy in measured dose respect to the Monte
Carlo curve at points far from the axis is appreciably greater for the CCX than for the CCA
plaque: at 10 mm from the axis that difference is 2.2% for the CCA plaque and 6.4% for the
CCX plaque. The measurements with radiochromic film by Kirov et al. (2005) for the CCX
plaque agree well with the measurements from this work even at distances far from the axis,
indicating that an inhomogeneous radioisotope distribution near the edges of the plaque is a
feature of the specific CCX plaques studied herein and in the work of Kirov et al. (2005).
4.3.3 Films at a plane containing the symmetry axis (PDD plane)
To study the setup repeteability two films were irradiated using the CCA 1440 plaque. Since
the films were irradiated during different time (150 and 130 min), the dose distributions were
normalized at a depth of 2 mm (Figure 4.11). The measured distributions were registered
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FIGURE 4.6: Measured dose plane perpendicular to symmetry axis for the CCA 1440
plaque compared to Monte Carlo simulation results. (a) Average of measured dose
distributions against simulated dose distribution. Both dose distributions were nor-
malized to the value of the corresponding central bins. (b) Gamma index map with
criteria of 3%/0.5 mm shows that 68.3% of the analyzed bins have a γ index equal
or less than 1. The reference set was the average of measured dose distributions. (c)
Same as (b) but with criteria 6%/1 mm increases the agreement to 91.3%.
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FIGURE 4.7: Measured dose plane perpendicular to symmetry axis for the CCX 228
and the CCX 250 plaques. (a) Normalized measured dose for the CCX 228 plaque.
(b) Normalized measured dose for the CCX 250 plaque. (c) Comparison of measured
dose maps of the CCX 228 and the CCX 250 plaques. (d) Gamma index map for
criteria of 3%/0.5 mm, resulting in a percentage of agreement of 99.1%. The CCX 228
was taken as the reference set, and the CCX 250 was taken as the evaluated set. It was
checked that the results are very similar if we exchange the reference and evaluated
sets.
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FIGURE 4.8: Measured dose plane perpendicular to symmetry axis for CCX plaques,
compared to Monte Carlo simulation results. (a) Average of measured dose distri-
butions against Monte Carlo dose distribution for the CCX 228 and the CCX 250
plaques. Measured and estimated dose distributions are normalized to the value
of the central bin of each dose distribution. (b) Gamma index map with criteria of
3%/0.5 mm. The obtained percentage of agreement was 56.9%. (c) Same as (b) but
with criteria of 7%/0.5 mm increases the agreement to 99.4%. For the gamma evalu-
ations, the measured dose distribution was used as the reference set.
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FIGURE 4.9: LEFT: Example of dose values measured by the manufacturer with a
plastic scintillator at points located at 1 mm from the plaque’s inner surface, as they
are printed in the calibration certificate of the plaques. RIGHT: Radial averages of
the aforementioned dose values for the plaques studied in this work. The differences
between CCX and CCA plaques at the ‘5 mm outside’ position are consistent with
the film measurements from this work and with the results from Kirov et al. (2005).
with a rigid transformation to correct minor misalignments and rotations. A gamma index
analysis was performed to evaluate the agreement between each measured dose distribution
and the bin–by–bin arithmetic mean of the two measured dose distributions. This setup is
not as repeatable as the setup to measure perpendicular dose planes, as the gamma criteria
needed to obtain acceptable agreements were 7%/0.7 mm, with percentages of agreement of
91.7% and 91.4% for each of the irradiated films. The disagreement occurs mostly at the points
near the surface of the plaque.
Figure 4.12 shows the comparison between the average of the measured dose distribu-
tions for the CCA 1440 plaque and the simulation results. The agreement for the medium
and low isodose lines is good, but differences of up to 25% occur at 1 mm from the plaque
surface. These differences are reduced to below 5% at distances greater than 2 mm. This is
not surprising as the measurements shown in Figure 4.5 prove that this plaque has an inho-
mogeneous radioisotope distribution. With gamma criteria of 3%/0.5 mm the agreement is of
83.6%, and with criteria of 7%/0.5 mm the agreement increases to 92.7%. Similar differences
near the plaque surface between film measurements and Monte Carlo simulation results were
also reported by Heilemann et al. (2015), with differences up to 15% within the first 1.5 mm.
A contributing factor to the differences could be the effect of the nail polish applied to the film
edges. Hence, we recommend not to use the first 1.0–1.5 mm from the film edge to obtain
dosimetric information for the films irradiated with the proposed technique.
For the CCX model only one film was available for analysis, corresponding to the CCX
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FIGURE 4.10: Profiles along the X axis at a depth of 5 mm extracted from the mea-
sured 2D dose distributions. TOP: average of three measurements of the CCA 1440
plaque and Monte Carlo simulation results from this work. BOTTOM: average of
two measurements (for the CCX 228 and the CCX 250 plaques), Monte Carlo sim-
ulation results, and dose profile measured by Kirov et al. (2005) with radiochromic
film. Uncertainty bars (shown each five experimental points) for measured profiles
correspond to 3.8% for dose standard uncertainty, and to 0.5 mm for positioning un-
certainty. Standard statistical uncertainty for simulated profiles is below 0.3% and
uncertainty bars are not shown for clarity.
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FIGURE 4.11: Measured dose planes containing the symmetry axis of the CCA 1440
plaque. (a) and (b): Dose distributions from two independent measurements nor-
malized at a depth of 2 mm from the film edge along the symmetry axis. (c) and (d):
Comparison of isodose lines for each measured distribution respect to the average of
both distributions. (e) and (f): Gamma analysis of each measured distribution (eval-
uation set) respect to the average of both distributions (reference set), with criteria of
7%/0.7 mm. The percentages of agreement were 91.7% (e) and 91.4% (f).
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FIGURE 4.12: Average of the measured dose distributions at a plane containing the
symmetry axis for the CCA 1440 plaque, compared to the Monte Carlo simulation
results obtained in chapter 2. (a) Comparison of isodose contours normalized at
a depth of 2 mm from the film edge along the symmetry axis. (b) Gamma index
map with criteria of 3%/0.5 mm shows an agreement of 83.6%. (c) Gamma index
map with criteria of 7%/0.5 mm increases the percentage of agreement to 92.7%.
The average of the dose distributions was used as the reference set for the gamma
analysis.
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FIGURE 4.13: Measurement of a dose plane containing the symmetry axis for the
CCX 228 plaque. (a) Measured dose distribution. (b) Measured dose distribu-
tion compared to Monte Carlo simulation results. (c) Gamma index map from the
comparison between measured and Monte Carlo dose distributions with γ crite-
ria of 3%/0.5 mm. Poor agreement: 80.9%. (d) Same as (c), but with γ criteria of
15%/0.5 mm increases the agreement to 96.6%.
228 plaque (Figure 4.13). As in the case of the CCA 1140 plaque, the agreement between
measurement and simulations is rather good for depths greater than 2 mm (dose differences
below 5%), but there is a large disagreement (up to 20% in dose difference) in the first 1.5 mm.
Depth–dose curves were extracted from the measured dose distributions to compare with
published results of measurements for the CCA and CCX models (Figures 4.14 and 4.15).
These data previously appeared on Figures 2.13 and 2.15. The first 1.5 mm from the film edge
were not considered in the comparisons.
The measured data in water from this work for the CCA plaque are in excellent agreement
within the experimental uncertainty (differences below 2%) with the measurements by Heile-
mann et al. (2015), which were carried out in a plastic phantom. Our measurement results
also show a better agreement with Monte Carlo simulation results than the measurements of
Taccini et al. (1997) using an early model of radiochromic film (Gafchromic types 37–041 and
37–040), which reached differences from 4.6% at 6.0 mm deep to 6.0% at a depth of 3.0 mm.
For the CCX 228 plaque, the measurements from this chapter agree well with the Monte Carlo
simulation results from chapter 2 and with the measured data stated in the plaque calibration
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FIGURE 4.14: Relative depth–dose curve for the CCA plaque extracted from the
measurements of this work using EBT3 radiochromic film compared with available
published experimental results.
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certificate, which were obtained by the manufacturer with a scintillation dosimeter.
To conclude, the setup proposed in this chapter to measure depth–dose curves in water
for 106Ru/106Rh plaques with the EBT3 film provides results of similar or better quality than
those published using radiochromic films with plastic phantoms, or with other detectors.
4.3.4 Estimation of measurement uncertainties
To estimate the combined standard uncertainty of the measured dose distributions obtained
with the experimental setups proposed in this chapter, the following sources of uncertainty
affecting the film calibration and measurement steps were analyzed:
1. Determination of the absorbed dose to water under reference conditions produced by
the clinical linear accelerator used in the calibration of the films: this procedure includes
uncertainties related to the standard laboratory where the reference ionization chamber
is calibrated, as well as uncertainties related to the measurement of the dose at the hospi-
tal. According to the TRS–398 dosimetry protocol (IAEA, 2001), for high energy photon
beams the combined relative standard uncertainty of this procedure is estimated to be
about 1.5% (combination of type A and type B uncertainties).
2. Accuracy of the Eclipse calculation to obtain the monitor units needed to give the de-
sired doses to the film in the PMMA phantom: comparison from the Eclipse calcula-
tion and measurements with ionization chamber in the PMMA phantom gives a relative
standard uncertainty of 0.3%, determined from repeated measurements (type A uncer-
tainty).
3. Stability of the clinical linear accelerator output: the associated relative standard un-
certainty was determined from repeated measurements (type A uncertainty), giving a
value of 0.1%.
4. Difference in energy dependence of EBT3 film between water and PMMA: this contri-
bution must be assessed as the calibration was made with the films in a PMMA phan-
tom, whereas the measurements of the dose distributions produced by the 106Ru/106Rh
plaques were made with the films immersed in water. The mean value of the differ-
ence in absorbed–dose–to–water energy dependence g(Q) between water and PMMA
in the range 10 keV–6 MeV was 1.7%, according to the results from chapter 3, which
were obtained with standard statistical uncertainties below 1%. As no additional infor-
mation is available, it is recommended to assume a rectangular probability distribution,
from which we can derive a value of 1.7%/
√
3 ' 1.0% for this type B standard uncer-
tainty (Bureau International des Poids et Mesures, 2008).
5. Difference in energy dependence of EBT3 for electrons respect to 6 MV photons: Sip-
ilä et al. (2016) studied the dosimetric characteristics of the EBT3 film to use it in elec-
tron and photon/electron beams. They found that the dose response of the EBT3 film
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was uniform within 1%, with a standard uncertainty about 0.8%. As in the previous
paragraph, we assume a rectangular probability distribution, resulting in a value of
1.0%/
√
3 ' 0.6% for this type B standard uncertainty (Bureau International des Poids
et Mesures, 2008).
6. The uncertainty associated to the dose calibration process was estimated through the
consistency of the calibration. Once the fit was made, the fitted function was applied
to the same ROIs used to obtain the fit parameters, and the average dose obtained were
compared with the doses assigned to those ROIs in the calibration. The relative consis-
tency was expressed as the difference in percentage between the average doses read on
the ROIs and the assigned doses. This relative consistency was taken as the estimated
standard uncertainty of the calibration for the films irradiated to doses in the range 0.5–
10 Gy, and the obtained value was 1.4%.
7. Interscan uncertainty: determined from repeated scans of the same film (type A uncer-
tainty). The repeated measurements were carried out with the warmed–up scanner. The
relative standard uncertainty was taken as the standard deviation of the mean dose in a
selected ROI for a series of repeated scans. This value resulted to be 0.3%.
8. Setup repeteability: assessed from the gamma index analysis of repeated measurements
for each setup. The dose criterion needed to obtain a satisfactory agreement in the
gamma analysis of the available repeated measurements was assumed to be similar to
the relative standard dose uncertainty of the setup (type B uncertainty). The values ob-
tained were 3% for the setup to measure dose planes perpendicular to the symmetry
axis of the plaques at a film–plaque distance of 5 mm, and 7% for the setup to measure
PDD planes. This uncertainty contribution includes the dose uncertainty due to the ir-
radiation of the film during the film positioning which was estimated to be of 0.3% for
the perpendicular dose planes, and of 0.7% for the PDD planes. The setup repeteability
uncertainty also includes the interscan uncertainty of item 7.
To estimate the total uncertainty of the measured dose distributions, the contributions 1–6
and 8 above were combined in quadrature, giving relative standard uncertainties of 3.8% for
absorbed dose distributions measured at planes perpendicular to the symmetry axis of the
plaques and at a film–plaque distance of 5 mm, and of 7.4% for PDD dose planes.
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Chapter 5
Discussion
The preceding chapters already presented some discussion and conclusions on the specific
issues of each chapter. Below a discussion is offered on the limitations of the methods used,
the possible influence of the results from this thesis on the clinical practice of ophthalmic
brachytherapy with 106Ru/106Rh plaques, and suggestions for future research.
5.1 Limitations
The EBT3 film model used in this work was designed to improve the features of the older
EBT2 model, specially to reduce the energy dependence at low energies (Bekerat et al., 2014).
The study presented in chapter 3 evaluated the absorbed–dose energy dependence of the
EBT3 film for photon beams only. The reason was to compare with published results for older
film models by Sutherland and Rogers (2010), and with the results by Bekerat et al. (2014),
who studied the effect of varying the atomic composition of the active layer on the energy
dependence of the EBT3 film. The main objective in chapter 3 was to assess the influence of
the phantom material on the EBT3 absorbed–dose energy dependence. This influence was
assessed for photons only, as previous publications have shown that the EBT3 film energy
response is almost independent of the type of radiation (Sorriaux et al., 2013; Sipilä et al.,
2016). An additional evidence proving the equivalent behavior of the EBT3 film with photon
and electron beams is shown on Figure 5.1. The figure shows the dose calibration functions
for EBT3 films from the same lot irradiated with a 6 MV photon beam and with a 4 MeV
electron beam, both from a Varian Clinac 2100 clinical electron linear accelerator. The photon
and electron curves are compatible within the experimental uncertainty12.
The main limitation of the experimental measurements from chapter 4 is the reduced num-
ber of measured plaque models (CCA and CCX only). No more plaque models were available.
Moreover, due to logistic limitations, a small number of repeated measurements was possible.
Although it would be desirable to have more measurements, it is unlikely that the conclusions
of this work would be affected in a relevant way. Another limitation of the experimental setup
was the manual trial–and–error procedure to make sufficiently accurate molds.
12 These measurements were performed by Juan Francisco Calvo Ortega, M.Sc. from the Department of Radia-
tion Oncology, Hospital Quirón, Barcelona, Spain.
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FIGURE 5.1: Dose calibration functions for EBT3 films irradiated with a 6 MV pho-
ton beam and with a 4 MeV electron beam, both from a Varian Clinac 2100 clinical
electron linear accelerator. The photon and electron curves are compatible within
the experimental uncertainty for all color channels. Measurements courtesy of Juan
Francisco Calvo Ortega, M.Sc. from the Department of Radiation Oncology, Hospital
Quirón, Barcelona, Spain.
5.2 Implications for the clinical practice
The results obtained in this thesis may influence the clinical practice at different levels. The ab-
sorbed dose to water distributions obtained from the simulations presented in Tables 2.2–2.4
from chapter 2 can be useful to perform independent checks of treatment planning calcula-
tions. As an example, Figure 5.2 shows a comparison between the Monte Carlo simulation
results from chapter 2 and calculations made with the Plaque Simulator software (v. 5.3.6),
taken from a work that the author of this thesis co–authored with Cano-Herranz et al. (2014).
Nowadays, no commercial device or recommended method are available to perform qual-
ity control tests to check the dose distributions and the absolute dose rate of the 106Ru/106Rh
plaques used in the clinical practice. Thus, users may be forced to rely only on the calibration
certificates provided by the manufacturer. The experimental setups proposed in chapter 4
allow users of 106Ru/106Rh plaques to measure in a practical way the dose distributions in
water produced by the specific plaques used for treatments. The materials needed are easily
affordable by a medical physics department, without the need of specifically machined solid
phantoms (Taccini et al., 1997; Soares et al., 2001; Kovacˇevic´ et al., 2005; Barbosa et al., 2015;
Heilemann et al., 2015).
It is a common practice in brachytherapy that scientific societies propose consensus data
for the most used sources, based on meta–analysis of published experimental and simulation
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FIGURE 5.2: Comparison of isodose lines at a plane containing the symmetry axis
of the CCA plaque, between the Monte Carlo simulation results from chapter 2 and
calculations with the Plaque Simulator software, as shown by Cano-Herranz et al.
(2014). The depth of normalization is 1 mm from the surface of the plaque.
studies. However, no such consensus data exists for 106Ru/106Rh ophthalmic plaques. A re-
port just published (June 1, 2016) (Nath et al., 2016) by the Task Group 167 of the American As-
sociation of Physicists in Medicine stresses the importance of having a good characterization
of the dose distribution produced by brachytherapy sources before its clinical use, via Monte
Carlo simulations and/or experimental measurements. In the absence of consensus data, the
report recommends the medical physicist to use candidate datasets taken from the literature.
The simulation results from chapter 2 are in good agreement (about 3%) with the available
data in the literature and with the experimental measurements from chapter 4. Moreover, the
analysis presented in chapter 2 allowed to identify some shortages on previous publications,
and to find out the causes of some discrepancies in the literature. Hence, the data set from the
Monte Carlo simulations obtained in this research are the most comprehensive and reliable
data available on dose distributions of 106Ru/106Rh plaques and may well constitute the basis
for the first consensus dataset for these plaques.
5.3 Future research
Regarding the simulation of the dose distribution produced by the plaques, an improvement
could be achieved by considering in the simulation the actual radioisotope distribution, in-
stead of considering an ideal homogeneous distribution. This suggestion poses two major
challenges: the measurement of the actual radioisotope surface distribution and the use of an
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arbitrary radioisotope surface distribution as a source for Monte Carlo simulations. Eichmann
et al. (2009) measured the surface dose rate distribution of 106Ru/106Rh plaques with a plastic
scintillator mounted on a system that was capable of guiding the detector across the plaque
surface at a constant small separation. From this surface dose rate distribution, it is possible to
estimate the actual radioisotope distribution. The use of an arbitrary radioisotope distribution
as a source for Monte Carlo simulation represents a non–trivial problem because the available
codes do not allow this to be carried out easily. Some preliminary results of simulations using
actual emitter distributions, obtained with the device developed by Eichmann et al. (2009),
were presented by Brualla et al. (2016) at the 22. Jahrestagung der Deutschen Gesellschaft für
Radioonkologie (Mannheim, June 2016). The estimated dose distributions using the actual
emitter distribution were compatible with the experimental depth dose profiles measured in
water by the manufacturer of the plaques. A topic of research would be to develop an algo-
rithm to derive the actual radioisotope distribution from film measurements perpendicular to
the symmetry axis of the plaque as those performed in this thesis.
Another line of research is the development of variance–reduction techniques designed
to improve the efficiency of the simulations. The rationale is to simulate the 106Ru/106Rh
plaques in clinical conditions, that is, using computed tomography images from real patients
as previous works have done (Brualla et al., 2013), while obtaining the calculation results in
a time–frame adequate for the routine clinical practice. The results from the simulations in
this thesis could be used as a benchmark for those that would be obtained using variance–
reduction techniques.
This thesis is framed within a far–reaching project, namely, the development of a Monte
Carlo treatment planning system for ophthalmic brachytherapy with 106Ru/106Rh plaques.
This system would be inspired on PRIMO13 (Rodríguez et al., 2013), a user–friendly software
that simulates clinical linear accelerators and estimates absorbed dose distributions in water
phantoms and computed tomography datasets. PRIMO includes a graphical user interface
to perform simulations with the PENELOPE code. We propose the following minimal features
for a system devoted to the simulation and planning of treatments with 106Ru/106Rh plaques:
(i) the dose calculation engine would be based on Monte Carlo simulation with PENELOPE;
(ii) the simulations would be performed on the CT of the actual patients (Brualla et al., 2013),
rather than on a model of the eye composed of water as Plaque Simulator does; (iii) the dose
dataset obtained in this thesis could be used to obtain a fast dose estimation during the plan-
ning process. When a plaque and location were decided, the final dose simulation would be
performed using the actual radioisotope distribution for the particular plaque used, as de-
scribed by Brualla et al. (2016); (iv) the aforementioned variance–reduction techniques could
be used to obtain an accurate dose estimation in a short time.
13 PRIMO is free software that can be downloaded from http://www.primoproject.net.
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Chapter 6
Conclusions
The research presented in this thesis improved the knowledge on the absorbed–dose to water
distributions produced by 106Ru/106Rh ophthalmic plaques. The conclusions are related to
the objectives stated in chapter 1 and they are presented in the corresponding order:
1. The Monte Carlo code for radiation transport PENELOPE was used to simulate twelve
106Ru/106Rh plaque models. Absorbed dose distributions in water were obtained. A
good agreement was found (generally within 3%) with published measurement data
and with measurements performed in this work with the EBT3 radiochromic film. Com-
parison with the literature allowed to find causes of deficiencies in previous publica-
tions. The data set from the Monte Carlo simulations obtained may well constitute the
basis for the first consensus dataset for these plaques.
2. A simulation study with PENELOPE was carried out on the influence of the phantom
material on the absorbed–dose energy dependence of the EBT3 radiochromic film. Solid
phantom materials commonly used in film dosimetry were analyzed and compared to
water, the reference material. The results confirmed an improvement in the absorbed-
dose energy dependence of the EBT3 film respect to older models when irradiated in
water. The maximum difference of the EBT3 energy dependence with the solid phan-
toms studied respect to water is about 6%, found at an energy of 50 keV. Moreover, the
reported overall energy dependence of the EBT3 film in water at energies below 100 keV
was found to be due to the intrinsic energy dependence.
3. A practical experimental method was developed for measuring in water the 2D ab-
sorbed dose distributions and the absolute dose rates produced by 106Ru/106Rh plaques,
using the EBT3 radiochromic film. Experimental results for dose planes containing the
symmetry axis of the plaques, and dose planes perpendicular to it were obtained for the
CCA and CCX plaque models. The measured absolute dose rates agreed with the values
quoted in the calibration certificates of the plaques within the experimental uncertainty,
with typical differences below 5%. The relative standard uncertainties obtained were
of 3.8% for dose distributions measured at planes perpendicular to the symmetry axis,
and of 7.4% for planes containing the symmetry axis (depth–dose planes). These values
are comparable to those reported by other authors using plastic phantoms, but avoiding
uncertainties associated to the conversion from dose–to–plastic to dose–to–water.
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Chapter 7
Abstract
Eye cancer is an uncommon disease. Despite its low incidence, ocular tumors such as uveal
melanoma and retinoblastoma can be life–threatening in many cases. For small–to–medium
ocular tumors, brachytherapy with radioactive 106Ru/106Rh plaques offers good outcomes in
terms of local control and disease–free survival. Although these plaques have been used for
decades, the measurement and calculation of the produced dose distributions remain chal-
lenging tasks. This thesis aims at improving the current knowledge on the theoretical and
experimental dosimetry of 106Ru/106Rh plaques.
First, we used Monte Carlo simulation of radiation transport to estimate accurate absorbed
dose to water distributions produced by twelve plaque models. Secondly, we developed a
practical experimental technique to measure in water the planar dose distributions produced
by the plaques. For this experimental validation the EBT3 radiochromic film model was used
which, in turn, required to characterize the absorbed–dose energy dependence of this new
film model by means of Monte Carlo simulation. A detailed uncertainty analysis was carried
out for simulation and experimental results. Both the simulated and measured absorbed dose
distributions were compared with the available literature.
The simulated dose distributions agreed within 3% with published data and with the EBT3
measurement results. Some discrepancies from the literature were also solved. This is the first,
and currently unique, comprehensive dosimetry dataset for 106Ru/106Rh plaques. Therefore,
it can become the basis for the first consensus dataset available. This dataset could also be
useful for quality assurance of treatment planning systems.
The simulation of the EBT3 film confirmed an improvement in the absorbed-dose energy
dependence for this film model respect to older models. Applications for this film are found
in many areas of medical physics.
The measured dose distributions achieved a good agreement in absolute dosimetry with
measurements by the manufacturer, and in relative dosimetry with the simulation results.
The proposed method would allow users to check absolute dose distributions close to the
plaque surface, and directly in water, thus avoiding the conversion from dose–to–plastic to
dose–to–water, as it would occur if solid phantoms were used. With this method, a smaller
experimental uncertainty was attained respect to the manufacturer and other authors.
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